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ABSTRACT

microRNAs (miRNAs) are short sequences of RNA that function as negative
post-transcriptional regulators of gene expression. Their effects are mediated through
direct binding to target messenger RNAs. Studies describing the crucial role of miRNAs
in osteoclasts are quite limited. The aim of this work was to investigate the basic
mechanisms by which miRNAs control osteoclast differentiation and activity.
miR-29

Promotes

Murine

Osteoclastogenesis

by

Regulating

Osteoclast

Commitment and Migration. The expression of miR-29 family members increases during
osteoclast differentiation, and its inhibition impairs commitment and migration of the
progenitors. In an effort to understand how miR-29 exerts its function, we demonstrated
that miR-29 negatively regulates RNAs critical for cytoskeletal organization and RNAs
expressed in the macrophage lineage, as well as Calcitonin receptor, which controls
osteoclast survival and resorption.
Pathway

analysis

of

microRNA

expression

profile

during

murine

osteoclastogenesis. Microarray analysis was used to profile the expression of miRNAs
during the course of osteoclast differentiation, in an enriched population of osteoclast

Tiziana Franceschetti - University of Connecticut, 2014
progenitor cells from murine bone marrow. Computational analyses were used to predict
functional pathways that may be regulated by clusters of miRNAs in osteoclasts. The
most prominent pathways identified include those involved in cell motility, cell-matrix
interactions, axon guidance, and cytoskeletal remodeling. These processes are critical for
the migration of osteoclast precursors, their maturation, and bone resorbing activity.
These studies contribute to our understanding of miRNA function in the
osteoclast lineage. This information could be used to develop therapies for skeletal
diseases associated to alterations in the bone resorption compartment.
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CHAPTER 1:
INTRODUCTION
Osteoclast Biology and Regulation by microRNAs

Bone is a highly dynamic tissue, continuously remodeling itself to repair damaged
bone matrix and to fulfill the metabolic needs of the organism. Bone remodeling is
achieved through a delicate balance between bone formation, which is mediated by
osteoblasts, and bone resorption, which is accomplished by osteoclasts (1). Specific
factors are produced by osteoblasts and osteoclasts to ensure that bone resorption is
coupled to bone formation during physiological bone remodeling, to preserve the
microarchitecture of bone. Continuous cell-cell communication between osteoblasts and
osteoclasts, through physical interaction and exchange of soluble factors, allows the bone
cells to regulate each other’s differentiation and activity.
Bone is remodeled to respond to hormonal cues or when nutritional modifications
require mobilization of minerals from the skeleton. Furthermore, skeletal remodeling can
regulate proliferation and differentiation of the cells of the bone marrow niche, a stem
cell-rich compartment that is comprised of numerous hematopoietic and mesenchymal
progenitors. Therefore, skeletal homeostasis is critical for the maintenance of bone
health.
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Alterations in osteoclast differentiation or resorption activity can lead to an
imbalance in the bone remodeling compartment, which is associated with the
development or progression of debilitating pathological conditions. These include
osteoporosis, osteopetrosis, rheumatoid arthritis, and multiple myeloma (2-7). Decoding
the complex regulatory pathways that underlie osteoclast differentiation and activity is a
crucial step in the development of new therapeutic strategies to treat disorders of bone
remodeling. Considerable research efforts have contributed to characterizing the
processes that regulate osteoclastogenesis and bone resorption at the transcriptional and
post-translational levels.
microRNAs (miRNAs) are a rather novel class of regulators of gene expression,
and they control key cellular processes, including differentiation, proliferation, and
survival. miRNAs are short (20-25 nucleotide-long), single-stranded sequences of RNA,
which post-transcriptionally inhibit the expression of specific target genes (8). The
importance of miRNAs in skeletal biology has been extensively investigated, with
particular focus on osteoblasts and chondrocytes (9). However, the role of specific
miRNAs in the osteoclast lineage is still widely uncharacterized.
The goal of this Introduction is to summarize our knowledge of the mechanisms
regulating osteoclast differentiation and activity, and describe the most recent studies on
the role of miRNAs in the osteoclast.
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I. Osteoclasts.
I.1. Osteoclast differentiation.
Osteoclasts are specialized cells that resorb bone, and their differentiation is an
intricate, multi-step process (Figure 1.1). Osteoclasts derive from multipotential
hematopoietic precursors, which can also give rise to erythrocytes, platelets, and cells of
the immune system. Osteoclastogenesis initiates with the differentiation of common
myeloid progenitors, which
can

form

monocytes-

macrophages, granulocytes,
and

megakaryocytes.

In

response to a number of
osteoclastogenic
monocyte
proliferate,

stimuli,
precursors

migrate,

and

commit to the osteoclast
lineage, at the expense of
the alternative macrophage
fate. Osteoclast precursors
then

fuse

into

a

multinucleated polykaryon,
which can be activated to

Figure 1.1. The process of osteoclastogenesis.
Schematic representation of the various phases of
osteoclast differentiation. Key transcriptional regulators
and marker genes of each step are indicated.
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resorb bone, triggering the bone remodeling process (2, 10). Although multinucleation is
not necessary for bone degradation, it was shown that resorption efficiency is directly
proportional to size of the mature osteoclast. The activated osteoclast has a limited life
span, and will physiologically undergo apoptosis, to protect the skeleton from excessive
bone resorption.

I.2. Osteoclast function.
Osteoclasts adhere to the bone surface through the interaction of integrin αvβ3
with Arg-Gly-Asp (RGD) motifs on extracellular matrix proteins, such as osteopontin
and bone sialoprotein. Mature, activated osteoclasts then need to become polarized in
order to begin the resorption process (Figure 1.1). To accomplish this, osteoclasts
perform an extensive reorganization of the cytoskeleton (11, 12). Polarized osteoclasts,
rich in mitochondria that produce energy necessary for resorption, position the nuclei in
the apical part of the cell. In contrast, in the basal region, cytoskeletal remodeling allows
the formation of specialized, actin-rich structures, called podosomes, used by the
osteoclasts to attach to the bone matrix (Figure 1.1). Here, actin filaments interact with
cytoskeletal proteins, including α-actinin and vinculin. The arrangement of several
podosomes into a dynamic circular structure (podosome belt) leads to the formation of
the sealing zone, which creates an isolated extracellular compartment, known as the bone
resorption lacuna (11, 13, 14).
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The basolateral membrane of the polarized osteoclast, called the ruffled border, is
responsible for resorption. This is achieved by establishing an acidic environment in the
resorption lacuna, with the combined action of carbonic anhydrase II, H+/ATPase proton
pumps, ClC-7 chloride channels, and HCO3-/Cl- exchangers. Carbonic anhydrase initiates
the acidification process by producing protons and HCO3-, as a result of CO2 hydration
(15). By means of secretory vesicles and H+/ATPase pumps, H+ ions are transported
through the ruffled border into the resorption pit (16). Vacuolar H+/ATPase works in
combination

with

ClC-7

channels

to

secrete

Cl-

ions

into

the

resorptive

microenvironment (16). Energy-independent HCO3-/Cl- exchangers, located in the apical
membrane of the osteoclast, are responsible of maintaining the intracellular pH (17). The
acidification step is necessary to dissolve the inorganic components of the extracellular
mineralized matrix.
Different matrix proteases, such as matrix metalloproteinase 9 (MMP-9) and
tartrate resistant acid phosphatase (TRAP), participate in the degradation of extracellular
matrix proteins (Figure 1.1) (18, 19). However, a major role is played by Cathepsin K, a
cysteine protease that is also secreted through the ruffled border, which degrades the
organic constituents of bone, comprised primarily by type I collagen fibers (Figure 1.1)
(4). The degradation products are endocytosed by the resorbing osteoclast, transported at
the apical membrane, and secreted into the extracellular compartment.
Bone resorption is very dynamic, and consists of cycles of osteoclast adhesion to
the bone surface, matrix degradation, and detachment. In a controlled manner, osteoclasts
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continuously reorganize the actin cytoskeleton into lamellipodia to migrate on the bone
surface, and to form new sealing zones, until they undergo apoptosis (11).

I.3. Regulation of osteoclast differentiation and function.
Osteoclast differentiation, activation, and survival are tightly regulated by a
combination of pro- and anti-osteoclastogenic hormones and cytokines. Among the proosteoclastogenic factors, Macrophage-colony stimulating factor (M-CSF, CSF1) and
Receptor activator of nuclear factor kappa-B (NFκB) ligand (RANKL) are essential and
sufficient for inducing osteoclast differentiation in vitro and in vivo (2, 20). In the
skeleton, these and other cytokines are produced by cells of the mesenchymal lineage:
stromal cells, osteoblasts, and osteocytes. However, osteoclast regulation is not limited to
these non-hematopoietic cells, and in the past decade the importance of immune cells in
the control of bone resorption has been described (21). Many of the molecules involved
in regulating osteoclast differentiation and activity were identiﬁed through the analysis of
animal models of naturally occurring genetic mutations, or transgenic gain-of-function or
loss-of-function mouse models displaying an osteopetrotic phenotype.

M-CSF.
M-CSF is a cytokine important for both the macrophage and the osteoclast
lineages. M-CSF signaling is activated upon binding to its receptor, c-Fms, which is a
member of the receptor tyrosine kinase (RTK) superfamily (Figures 1.1 and 1.2). M-CSF
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Figure 1.2. Signaling pathways in osteoclast differentiation. This model summarizes
the main intracellular signaling pathways activated by M-CSF and RANKL during
osteoclastogenesis.
binding to its receptor triggers the activation of several intracellular pathways, thereby
exerting its function on the osteoclast precursors. These complex signaling cascades are
not completely understood, but include activation of c-Src (cellular Src kinase), Syk
(spleen tyrosine kinase), PI3K (phosphoinositide 3-kinase), and ERK (extracellular
signal-regulated kinase) pathways (11).
M-CSF supports the survival and proliferation of the osteoclast precursor cells.
Further, M-CSF signaling promotes cytoskeletal reorganization and the migration of the
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osteoclast precursors. Importantly, M-CSF also activates the expression of the RANK
receptor on osteoclast progenitors, therefore priming them to respond to RANKL and
initiate osteoclast differentiation (10).

RANKL.
RANKL signals through RANK, a member of the tumor necrosis factor (TNF)
receptor superfamily, to promote osteoclast commitment, maturation, and survival
(Figures 1.1 and 1.2). Further, RANKL supports cytoskeletal remodeling, motility, and
bone resorption activity, thus acting as a key regulator of osteoclast differentiation and
function. The RANKL/RANK interaction activates the expression of osteoclast marker
genes, including TRAP, Cathepsin K, integrin β3, and calcitonin receptor (Figure 1.1) (2,
10, 22). Osteoprotegerin (OPG), also secreted by cells of the osteoblastic lineage and by
immune cells, is a decoy receptor for RANKL, thus a negative regulator of
osteoclastogenesis. Frequently, the relative abundance of OPG compared with RANKL
can determine whether osteoclast formation may ensue (23).
Like M-CSF, RANKL signaling is transduced by numerous intracellular
pathways, upon interaction of RANK with TNFR-associated cytoplasmic factors
(TRAFs), including TRAF6. In osteoclasts, RANKL mediates the activation, for
example, of the mitogen-activated protein kinase (MAPK) pathways involving c-Jun Nterminal kinase (JNK), p38 extracellular kinase (ERF), and ERK, as well as the inhibitor
of NFκB kinase (IKK) pathway, the PI3K pathway, and the Src pathway (11).
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Downstream effectors of these signaling cascades include several transcription factors
critical for the osteoclast lineage.

Transcriptional regulation of osteoclast differentiation.
Most of the transcription factors involved in the control of osteoclast
differentiation act as heterodimers to control gene expression. Purine-rich nucleic acid
binding protein 1 (PU.1) represents the earliest marker for osteoclastogenesis, and is
essential for the commitment of the myeloid progenitors into macrophage and osteoclast
precursors (24). Further, PU.1 regulates genes important for osteoclast function,
including Cathepsin K and osteoclast-associated receptor (Oscar) (Figure 1.1) (25, 26).
For the most part, PU.1 modulation of gene expression during the initial phases of
osteoclast differentiation is mediated by its interaction with microphthalmia-associated
transcription factor (MITF) (Figure 1.1) (26, 27). MITF has also been shown to
participate in the regulation of the osteoclast genes Clcn7, and osteopetrosis-associated
transmembrane protein 1 (Ostm1) (28).
RANKL signaling up-regulates the expression and the activation of NFκB, c-Jun,
and c-Fos, which are required for osteoclast differentiation and to induce osteoclast
marker genes (Figures 1.1 and 1.2). The NFκB family of transcription factors functions as
heterodimers, and are translocated into the nucleus to regulate gene expression (29). cJun and c-Fos belong to the activator protein 1 (AP-1) family, which is composed of
heterodimers of Fos and Jun proteins (30, 31). Importantly, NFκB, c-Jun, and c-Fos are
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involved in inducing the initial up-regulation of Nuclear factor of activated T-cells
cytoplasmic 1 (NFATc1), the master regulator of osteoclastogenesis (30).
In addition to RANKL signaling, other co-stimulatory pathways can initiate
NFATc1 expression during osteoclast differentiation. The RANKL-independent
pathways include the Ca2+ signaling pathway and the immunoreceptor tyrosine-based
activation motif (ITAM) proteins DNAX activation protein of 12 kDa (DAP12) and Fcreceptor common γ-subunit (FcRγ) (32). In the later stages of osteoclastogenesis,
NFATc1 binds its own promoter to amplify its expression (32).
NFATc1 is involved in the regulation of several aspects of osteoclast maturation
and activity (Figures 1.1 and 1.2). Either alone or in association with other transcription
factors, NFATc1 stimulates the fusion of the precursors into multinucleated cells, through
the up-regulation of the dendritic cell-specific transmembrane protein (DC-STAMP) and
the d2 isoform of vacuolar ATPase V0 domain (Atp6v0d2) (32). In addition, NFATc1
regulates osteoclast migration and adhesion to the bone surface. This is achieved by
directly promoting the expression of β3 integrin and c-Src, which trigger intracellular
pathways that converge on the reorganization of the cytoskeleton, orchestrated by small
GTPases of the Rho family (32). NFATc1 also promotes the expression of proteins
required for bone resorption: MMP-9, H+/ATPase, ClC-7, Cathepsin K, TRAP, calcitonin
receptor, and OSCAR (32).
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Osteoclast interaction with cells of the bone microenvironment.
As previously mentioned, bone resorption is coupled to bone formation, and
osteoclast differentiation and activity are strongly regulated in vitro and in vivo by the
action of cytokines, including M-CSF, RANKL, and OPG, produced by osteoblasts.
Further, recent reports indicate that RANKL is also expressed at high levels by terminally
differentiated osteocytes to support osteoclastogenesis (33, 34). Additionally, bidirectional signaling between osteoblasts and osteoclasts is achieved through the
interaction of ephrins and ephrin receptors. EphB4 receptors, expressed on the
osteoblasts, bind ephrin-B2, present of the surface of the osteoclasts. This interaction
promotes osteoblast differentiation and, at the same time, inhibits osteoclastogenesis (35).
In the bone marrow niche, osteoclasts are in close relationship with cells of the
immune system, which can secrete several regulatory cytokines (21). Macrophages
produce inflammatory factors, including interleukin 1 (IL-1), IL-6, and Tumor necrosis
factor α (TNFα). Although IL-1 alone cannot induce osteoclastogenesis, it stimulates
TRAF6 and potentiates the activation of the RANKL signaling pathway (2, 21).
Moreover, IL-1 promotes RANKL expression on cells of the osteoblast lineage, which
confirms the tight interaction of the cells within the bone microenvironment (21). TNFα
is a potent inducer of osteoclastogenesis, and it functions through a RANKL-independent
mechanism. This was demonstrated by the observation that TNFα-mediated osteoclast
differentiation is not blocked in the presence of OPG (36). Additionally, hematopoietic
precursors from RANKL-, RANK-, and TRAF6-null mice can form mature osteoclasts
when stimulated with TNFα (37).
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Activated T lymphocytes express RANKL, a pro-osteoclastogenic factor, but also
Interferon- (IFN-), IL-4, IL-10, IL-12, and IL-14, which are all inhibitory to osteoclast
differentiation (21). Therefore, the role of T cells on osteoclast differentiation may
depend on the ratios between these factors in specific biological conditions. Further, in
rheumatoid arthritis, T cells of the synovium produce large amounts of IL-17, which
induces RANKL secretion in synovial fibroblasts, and expression of TNFα, IL-1, and IL6 in synovial macrophages. These cytokines stimulate osteoclast differentiation,
promoting bone resorption and joint destruction (21, 38). Further, B lymphocytes are a
major source of RANKL and OPG in the bone marrow (39, 40).
The effect of specific cytokines on osteoclastogenesis also depends on the cellular
environment. For example, IL-7 has a direct inhibitory effect on osteoclastogenesis in
vitro (41). However, under inflammatory condition, IL-7 production by stromal cells and
osteoblasts stimulates the secretion of RANKL from T cells, which ultimately supports
osteoclast differentiation (42).

I.4. Identification of osteoclast precursors.
In the perspective of analyzing the mechanisms that orchestrate osteoclast
differentiation and activity, the use of a primary cell system is important. Peripheral
blood and bone marrow represent the main reservoirs of primary osteoclast precursors.
However, both of these sources are highly heterogeneous, which makes difficult the
analysis of osteoclast-specific mechanisms. In an effort to decrease the heterogeneity of
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primary cell cultures, several studies have adopted immunological techniques to deplete
contaminations from other hematopoietic populations.
Cell surface markers are routinely used to distinguish osteoclast precursors from
macrophages, dendritic cells, and B and T cells. A population of cells with high
osteoclastogenic efficiency can be isolated from mouse bone marrow, peripheral blood,
and spleen, which can be identified as negative for the lymphoid markers B220/CD45R
and CD3, present of B and T cells, respectively (43). These cells also present negative or
low expression of CD11b (also known as integrin alpha M, ITGAM), which is expressed
on several myeloid lineages and natural killer lymphocytes. Osteoclast precursors express
high levels of c-Fms (CD115) and c-Kit (CD117), a hematopoietic stem cell marker (43,
44). Additional studies have characterized the surface antigen profile of the osteoclast
precursors. Recently, osteoclast precursors were identified as CD3-/B220-/CD11b-/low
cells expressing high levels of Ly6C (lymphocyte antigen 6), a glycoprotein expressed on
most hematopoietic cells, and CX3CR1, a chemokine receptor expressed by monocytes
and lymphocytes. These cells appear to be distinct from a population of progenitors that
can give rise to not only osteoclasts, but also to macrophages and dendritic cells (45).
Species-specific differences in osteoclast cell surface antigens may also
complicate their characterization. CD14, a co-receptor for lipopolysaccharide, is a
commonly used monocyte marker used to isolate human osteoclast precursors (46, 47).
More recently, the osteoclastogenic potential of human peripheral blood monocytes was
differentiated based on the expression of DC-STAMP. This study showed that cells with
high levels of DC-STAMP generate more osteoclasts than the negative population (48).

13

In conclusion, combinations of surface markers are necessary to isolate osteoclast
precursor

cells,

in

order

to

further

investigate

the

mechanisms

regulating

osteoclastogenesis and bone resorption.

II. miRNAs.
II.1. miRNA biogenesis.
miRNAs are transcribed by RNA polymerase II as independent genes or included
in introns or exons of protein coding genes (Figure 1.3). miRNA-coding genes are
regulated similarly to protein-coding genes, and transcriptional control contributes to
their expression in specific cells, or tissues, or stages of development (8). Long primary
miRNAs (pri-miRNAs) contain typical hairpin structures, which, for the most part, are
cleaved by the nuclear endonuclease Drosha and the RNA binding protein DiGeorge
syndrome critical region gene 8 (DGCR8). The product, a ~60 nucleotide long precursor
miRNA (pre-miRNA), is exported into the cytoplasm by Exportin 5. Here, pre-miRNAs
are further cleaved by Dicer and the RNA binding protein transactivation-response RNAbinding protein (TRBP) into a miRNA duplex (8).
The miRNA duplex is then loaded onto an Argonaute protein (AGO). Mature
functional miRNAs can be derived from either the 5′-strand (indicated as -5p), or the 3′strand (indicated as -3p), or both strands of the pre-miRNAs (49). For the most part, the
functional miRNA strand is more abundant than the miRNA* or passenger strand, and
can be identified as the least thermodynamically stable strand in the complex. The active
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miRNA strand remains associated with AGO in an RNA-induced silencing complex
(RISC), which increases its stability, whereas the miRNA* passenger strand is eventually
degraded. The choice of the active miRNA strand is often tissue- or cell-specific (50).
The mature miRNA drives the RISC complex to bind target messenger RNA (mRNA)
sequences.

Figure 1.3. miRNA biogenesis and activity. Schematic representation of the miRNA
processing pathway and the primary mechanisms of miRNA-mediated inhibition of
gene expression.
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II.2. miRNA function.
Short, single-stranded mature miRNAs act, for the most part, as posttranscriptional, negative regulators of gene expression. Inhibition of gene expression is
mediated by direct binding to complementary sequences located on target mRNAs
(Figure 1.3). miRNA binding sites are frequently identified in the 3’ untranslated region
(UTR), although functional sites are recognized in the coding sequence and in the 5’
UTR. Inhibition of gene expression is achieved through different mechanisms, depending
on the degree of complementarity between the miRNA and the target mRNA. Nearperfect base-pairing frequently leads to the endonucleolytic cleavage of the mRNA
sequence and its destabilization, followed by degradation. This mechanism is typically
observed in plants, although it can also occur in mammalian cells (8).
More frequently, miRNA-target interactions are based primarily on the binding of
the nucleotides in positions 2-8 of the miRNA sequence, which are known as the “seed
region”. miRNA interaction with AGO determines the functional seed region. Here,
miRNA binding leads to the blockage of translational initiation, and mRNA decay upon
mRNA decapping or deadenylation. Additional features, other than base-pair
complementarity, contribute to the final outcome of each miRNA-mediated repression of
gene expression. These include the accessibility of the target site on the mRNA
secondary structure, the distance of the binding site to the 3’ end of the mRNA, as well as
the cellular localization and stability of the miRNA (51, 52).

16

II.3. miRNAs in osteoclasts.
Since they were first discovered, miRNAs have been widely investigated in
osteoblasts and in chondrocytes, where they are key regulators of skeletal development
and bone cell differentiation and function (9). In contrast, there are relatively few reports
on the role of miRNAs in osteoclasts, and a limited number of miRNA-target interactions
have been examined in this cell type. One major reason for this shortcoming could be that
the cell systems available for studying the mechanisms regulating osteoclastogenesis
have several limitations. For example, most of the mechanistic studies aimed at analyzing
miRNA function are performed using cell lines as tools. However, an immortalized cell
line for mature osteoclasts is not available, and the existing osteoclast precursor cell lines
have limited resorption activity. Further, as previously discussed, sources of primary
osteoclast precursors, such as the bone marrow, are extremely heterogeneous, which
makes necessary additional steps for cell isolation and sorting. These limitations likely
contribute to the deficit in our understanding of miRNA function in osteoclasts.

miRNA biogenesis pathway in the osteoclast lineage.
Initially, two independent studies analyzed the global role of miRNAs in
osteoclasts, by interfering with components of the miRNA biogenesis pathway. Sugatani
and colleagues silenced the expression of DGCR8, Dicer1, and Ago2 in vitro in mouse
primary bone marrow macrophages (BMMs) (53). These proteins are crucial for the
processing of the miRNA precursors and generation of the active mature miRNAs.
Knock-down of DGCR8, Dicer1, or Ago2 impaired the RANKL-mediated up-regulation
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of transcription factors important for osteoclastogenesis, including PU.1, MITF, c-Fos,
and NFATc1, as well as their recruitment to the NFATc1 and TRAP promoters. Further,
the expression of the osteoclast markers TRAP, MMP-9, Cathepsin K, Calcitonin
receptor, and integrin β3 were strongly attenuated by the suppression of the DGCR8,
Dicer1, or AGO2 levels. Consistently, osteoclast formation and bone resorbing activity
were decreased upon silencing of DGCR8, Dicer1, or AGO2 (53). These results indicate
the overall importance of the miRNA processing pathway in the osteoclast lineage.
In vivo, the role of miRNA biogenesis in osteoclasts was evaluated by generating
mouse lines with cell type-specific deletion of Dicer. Dicer deletion in myeloid cells,
using a CD11b promoter-driven cre, induced a mild osteopetrotic phenotype, with an
increase in bone formation parameters and decreased osteoclast number (53). Similarly,
Dicer ablation in mature osteoclasts using a Cathepsin K promoter-driven cre resulted in
increased bone mass, due to reduced osteoclast number (54). Therefore, these in vivo
phenotypes confirm that the miRNA biogenesis pathway is crucial for osteoclast
formation, as observed in vitro.
There is limited understanding of the mechanisms by which miRNAs regulate the
processes of osteoclast commitment, maturation, and function. Indeed, at the time of this
writing, only 9 miRNAs have been investigated in the osteoclast lineage (Table 1.1). An
overview of these miRNAs and their role in osteoclasts will be presented below.
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Table 1.1. miRNAs investigated in the osteoclast lineage.
miRNA

Known target
genes in OCS

Role
in
OCS

Experimental system

References

miR-124

NFATc1

-

BMMs

(55)

miR-146a

TRAF6

-

PBMCs

(56)

miR-148a

MAFB

+

PBMCs; mouse

(57)

miR-155

MITF; SOCS

-

RAW264.7; BMMs; mouse

(58-60)

miR-21

PDCD4

+

BMMs

(61)

miR-223

NFIA

+

RAW264.7; BMMs

(53)

miR-29

CTR, Cdc42,
srGAP2, NFIA,
CD93, GPR85

+

RAW264.7; BMMs

Chapter 3;
(62)

miR-31

RhoA

-

BMMs

(63)

miR-320a

ARF1

+?

PBMCs

Chapter 5;
(64)

miR-503

RANK

-

PBMCs; mouse

(65)

miR-223
miR-223 was the first miRNA with an identified role in osteoclasts. miR-223
expression is activated by PU.1, a transcription factor crucial in the early stages of
myeloid differentiation (24, 66). The expression levels of miR-223 are sustained in
primary bone marrow-derived osteoclast precursors and in the mouse monocytic cell line
RAW264.7, but decrease in a time-dependent manner during RANKL-driven
osteoclastogenesis (61, 67). In a study by Sugatani and colleagues, the authors reported
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that inhibition of the mature miR-223 with an antisense oligonucleotide impairs
osteoclastogenic differentiation in RAW264.7 cells, suggesting that miR-223 supports
osteoclastogenesis (53).
The pro-osteoclastogenic role of miR-223 is mediated, in part, through the
repression of the transcription factor NFI-A (53, 68). Down-regulation of NFI-A is
required for the differentiation of several hematopoietic cell types, including osteoclasts,
granulocytes, and monocytes. In contrast, NFIA is up-regulated during erythropoiesis
(53, 69, 70). Further, NFI-A negatively regulates the expression of the M-CSF receptor,
which is critical for osteoclast survival, maturation, and activity, as previously discussed
(12, 69). Therefore, miR-223 promotes osteoclast differentiation, in part, by targeting
NFIA.

miR-21
miR-21 expression is also induced by PU.1 and the AP-1 (activator protein 1)
family member c-Fos, transcription factors important for osteoclast differentiation and
function (71). miR-21 levels are up-regulated during the course of osteoclast
differentiation in RAW264.7 cells and in mouse bone marrow macrophages (BMMs) (61,
67). BMMs lacking key components of the miRNA processing machinery, either DGCR8
or Dicer, display impaired osteoclastogenesis. Forced over-expression of miR-21 in these
cells partially rescues their ability to differentiate into mature osteoclasts. Further, knockdown of miR-21 results in suppressed osteoclast formation and resorption activity of
bone marrow-derived macrophage cultures (Figure 1.4) (61).
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miR-21 represses the expression of PDCD4
(programmed cell death domain 4) in osteoclasts and
other

tissues

(61,

72).

PDCD4

inhibits

the

transcriptional activity of AP-1 family members, and
its over-expression robustly suppresses osteoclast
differentiation and function. Although other posttranscriptional targets of miR-21 may be involved,
PDCD4 inhibition represents one mechanism by
which

miR-21

promotes

osteoclastogenesis.

In

addition, miR-21 blocks the expression of FasL, an
estrogen (E2)-induced pro-apoptotic factor, thereby
protecting

osteoclast

progenitors

and

mature

Figure 1.4. The function of
miR-21 in osteoclasts. The
diagram
summarizes
the
regulatory loops that control the
expression of the miR-21, a
pro-osteoclastogenic miRNA.

osteoclasts from estrogen-mediated apoptosis. In a
regulatory loop, estrogen can inhibit miR-21 biogenesis, to limit its expression and allow
FasL translation, in order to restrict osteoclast survival (Figure 1.4) (73).

miR-148a
miR-148a expression is strongly induced during osteoclastogenesis in CD14+
human PBMCs (57). Over-expression of miR-148a in human PBMCs, as well as in
mouse BMMs, stimulates osteoclast differentiation and activity, whereas opposite effects
are produced by a miR-148a inhibitor. One of the genes that miR-148a regulates in
osteoclasts is the transcription factor MAFB (V-maf musculoaponeurotic fibrosarcoma
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oncogene homolog B) (57). MAFB inhibits the RANKL-driven transcriptional program
that promotes osteoclast differentiation (74). In vivo, inhibition of miR-148a, using a
specific oligonucleotide, elevated bone mass by decreasing bone resorption parameters.
This important in vivo experiment confirms the pro-osteoclastogenic role of this miRNA
(57). In addition, miR-148a levels are increased in circulating mononuclear cells from
systemic lupus erythematosus (SLE) patients, who display lower bone mineral density
(BMD). PBMCs from SLE patients have augmented osteoclastogenic potential, which is
restrained upon inhibition of miR-148a. Thus, elevated miR-148a likely contributes to the
increased osteoclastogenesis in SLE patients (57).

miR-31
RANKL treatment of mouse BMMs induces a strong up-regulation of miR-31, a
miRNA previously studied in cancer, but not in hematopoietic cells (63, 75). In
osteoclasts, miR-31 supports actin ring formation and bone resorption. This is achieved
because miR-31 tightly controls the expression of RhoA, a GTPase critical for
cytoskeletal organization, formation of the sealing zone, and osteoclast activity (63, 76).
Therefore, miR-31 promotes osteoclast formation and activity, and RhoA is a major
mediator of its function.

miR-155
As regulators of skeletal homeostasis, miRNAs with a negative role in osteoclasts
have also been identified. For example, pro-inflammatory signals, including TNFα and
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Interferon β (IFN-β), activate the expression of miR-155 during monocytic differentiation
and activation (59). miR-155 was shown to promote the commitment of monocyte
precursors to the macrophage lineage, at the expense of osteoclastogenesis (58). In
RAW264.7 cells, miR-155 over-expression impairs in vitro osteoclast formation and
resorption activity after treatment with M-CSF and RANKL. In particular, overexpression of miR-155 blocks the early stages of osteoclastogenesis, prior to fusion of the
precursors into multinucleated cells (58). In contrast, expression a miR-155 sponge
construct, which inhibits the function of miR-155, enhances osteoclast formation in
mouse BMM cultures (59).
The negative role of miR-155 on osteoclastogenesis is mediated by the repression
of the transcription factor MITF. As discussed in the previous section, MITF induces the
expression of key genes for osteoclast maturation and function: TRAP, OSCAR, and
Cathepsin K (77). In osteoclasts, as well as in other myeloid cells, miR-155 also inhibits
SOCS1 (suppressor of cytokine signaling 1), a protein that contributes to the signal
transduction of cytokines, such as IFN-β (59). By repressing the negative effects of proinflammatory cytokines on the differentiation of the progenitor cells, SOCS1 supports
osteoclastogenesis (78). Based on these findings, miR-155 down-regulates genes that are
important for the differentiation of the progenitor cells to osteoclastogenesis, therefore
favoring the macrophage fate.
Controversially, Blum and colleagues showed that, in an arthritis model, bone
marrow precursors from miR-155-null mice have reduced osteoclast potential (60).
Differences between this study and the in vitro findings by Zhang et al. suggest that miR-
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155 could play distinct roles in different phases of the multi-step process of
osteoclastogenesis. Therefore, a negative function of miR-155 on the commitment of the
precursors to the osteoclast lineage does not exclude its ability to support osteoclast
terminal differentiation. Alternatively, global miR-155-null mice may have decreased
osteoclast differentiation potential due to the effects of the miR-155-null mutation on
cells of other lineages, such as immune cells and osteoblasts.

miR-124
Similarly, miR-124 blocks osteoclast differentiation, and one of its targets is a
major pro-osteoclastogenic factor, NFATc1 (55). Activation of the osteoclastogenic
program by RANKL down-regulates miR-124 in mouse BMMs. Accordingly, overexpression of miR-124 inhibits osteoclast formation, whereas its knock-down promotes
differentiation. Moreover, the proliferation and migration of the osteoclast precursors are
diminished when miR-124 is over-expressed, suggesting that miR-124 regulates these
important processes in osteoclasts (55).

miR-146a
Expression of miR-146a inhibits the RANKL- or TNFα-induced osteoclast
differentiation of human PBMCs, as well as their bone resorption activity (56). miR-146a
plays an important role in inflammation, and is up-regulated in activated macrophages
(79). Additionally, in response to TNFα and IL-1β stimuli, NFκB drives miR-146
expression, and miR-146, in turn, targets TRAF6 (Tumor necrosis factor receptor-
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associated factor 6) and IRAK1 (IL-1 receptor-associated kinase), in a negative feedback
mechanism to limit NFκB signaling (80). TRAF6 is an ubiquitin ligase with a
fundamental role in osteoclast maturation, and its targeting by miR-146a likely represents
a key mechanism for repression of osteoclastogenesis. Further, in a mouse model of
arthritis, systemic administration of a miR-146a mimic prevents joint destruction and
bone erosion. This is achieved by reducing osteoclast number, providing an in vivo
confirmation of the negative role of miR-146a on osteoclastogenesis (56).

miRNAs and bone mass: miR-503 and miR-133
To correlate the function of specific miRNAs with the development of
pathological conditions, modifications in the miRNA expression profile of osteoclast
precursors have also been evaluated in selected cohorts of osteoporosis patients. For
example, dramatic down-regulation of miR-503 was detected in CD14+ peripheral blood
mononucleated cells (PBMCs) of post-menopausal osteoporosis patients (65). In vitro,
inhibition of miR-503 induces osteoclast differentiation of CD14+ PBMCs from healthy
subjects. Moreover, over-expression of miR-503 decreases osteoclast formation in
PBMCs from osteoporosis patients (65). miR-503 was found to regulate bone mass
through direct targeting of RANK (65). In vivo, administration of a miR-503 inhibitor
increases osteoclast formation, decreases bone mineral density (BMD), and reduces bone
resorption parameters, whereas systemic injection of a miR-503 mimic caused the
opposite bone phenotype (65). These results confirm that miR-503 expression negatively
impacts osteoclastogenesis. Further, the expression of miR-503 in osteoclasts is induced
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by estrogen, and decreased in ovariectomized (OVX) mice (65). Overall, these
observations suggest that miR-503 may play an important role in the development of
post-menopausal osteoporosis.
In contrast to miR-503, the expression of miR-133a is increased in circulating
monocytes from post-menopausal women with low bone mineral density (BMD). This
suggests that miR-133a may be a potential monocytic biomarker for post-menopausal
bone loss. However, the authors of this study failed to identify direct targets of miR-133a
which could mediate its function in bone resorbing cells, although this miRNA has been
investigated in osteoblasts and chondrocytes, where it targets Runx2 (81).

Conclusions
Bone homeostasis depends on the coupling of bone formation and resorption,
during the process of remodeling. Osteoclast differentiation, function, and survival must
be finely regulated to assure proper bone resorption activity. Understanding the molecular
mechanisms that participate in the regulation of osteoclastogenesis and bone resorption is
vital for the development of therapeutics for bone diseases characterized by alterations in
the osteoclast compartment.
Osteoblasts, osteocytes, and immune cells can regulate osteoclast differentiation
and activity. This is achieved through the expression of cell surface molecules and the
secretion of numerous soluble factors, including cytokines, hormones, growth factors,
and the decoy receptor OPG. On the osteoclast, these factors can trigger complex
intracellular signaling pathways, which converge in the activation of specific
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transcription factors that promote the expression of genes important for osteoclast
maturation and bone resorption.
However, post-transcriptional mechanisms also play an important role in
osteoclast differentiation and function, and miRNAs are key components of this process.
Only few miRNAs and target genes have been identified in the osteoclast lineage, where
they can modulate multiple aspects of osteoclast biology, including commitment and
migration of the precursors, maturation, resorption, and survival of the osteoclasts.
Clearly, additional studies are required to gain a more comprehensive knowledge of the
function of miRNAs in osteoclastogenesis.
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CHAPTER 2:

SPECIFIC AIMS AND HYPOTHESES

The overall aim of the studies described in this dissertation is to improve our
understanding of the basic mechanisms regulating the differentiation and function of
osteoclasts. This work will describe the miRNA-mediated post-transcriptional regulation
of key osteoclast genes, which could contribute to the development of novel therapeutic
strategies for bone diseases characterized by alterations of bone resorption.
We hypothesize that specific miRNAs fine tune gene expression to regulate
osteoclastogenesis, and, in particular, that: 1) miR-29 promotes osteoclast differentiation,
and 2) miRNA profiling of differentiating osteoclast precursors will highlight novel
miRNAs important for regulating osteoclast differentiation, and new genes and pathways
that play a role in this process.

Chapter 3: Specific Aim 1. To test the hypothesis that miR-29 promotes
osteoclastogenesis.
1a) To analyze the expression of the miR-29 family members during in vitro
osteoclastogenesis, we will utilize quantitative RT-PCR and examine RNA from
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differentiating cultures of mouse primary osteoclast precursors and of the monocytic cell
line RAW264.7.
1b) To investigate the function of miR-29 in the osteoclast lineage, we will analyze
osteoclastogenesis, proliferation, migration, and survival of RAW264.7 cells stably
transduced with a doxycycline-inducible construct for miR-29 knock-down (miR-29
sponge).
1c) To identify novel miR-29 targets in osteoclasts, we will use miRNA target prediction
algorithms (DIANA-microT 3.0, PicTar, miRanda, or TargetScan), and validate potential
miR-29 targets in the monocytic RAW264.7 cell line using Luciferase Reporter-UTR
assays.

Chapter 4: Specific Aim 2. To profile miRNA expression of differentiating osteoclast
precursors, and identify novel potential regulators of osteoclast differentiation and
function.
2a) To investigate the expression of mature miRNAs during osteoclastogenesis, we will
perform a miRNA microarray analysis on a bone marrow population enriched for
osteoclast precursor cells. We will determine miRNA expression in the early, middle, and
late stages of RANKL-driven osteoclastogenesis. Further, we will profile miRNA
expression in osteoclast cultures differentiated for 3 days with M-CSF and RANKL and
in undifferentiated cells cultured with M-CSF alone. The expression of selected miRNAs
will be confirmed by qPCR.
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2b) To identify genes and functional pathways that are potentially regulated by miRNAs
in the osteoclast lineage, we will perform a computational pathway prediction study for
differentially expressed miRNAs that were identified by the microarray analysis.
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CHAPTER 3:
miR-29 Promotes Murine Osteoclastogenesis by Regulating Osteoclast
Commitment and Migration

This work has been published: Franceschetti, T., Kessler, C.B., Lee, S.K., Delany, A.M. J
Biol Chem. 2013;288(46):33347-60.

CHAPTER ABSTRACT
Osteoclast differentiation is regulated by transcriptional, post-transcriptional, and posttranslational mechanisms. microRNAs (miRNAs) are fundamental post-transcriptional
regulators of gene expression. The function of the miR-29 (a/b/c) family in cells of the
osteoclast lineage is not well understood. In primary cultures of mouse bone marrowderived macrophages, inhibition of miR-29a, -29b, or -29c diminished formation of
tartrate-resistant acid phosphatase (TRAP)-positive multinucleated osteoclasts, and the
osteoclasts were smaller. qRT-PCR showed that all miR-29 family members increased
during osteoclast differentiation, in concert with mRNAs for the osteoclast markers Trap
(Acp5) and Cathepsin K. Similar regulation was observed in the monocytic cell line
RAW264.7. In stably transduced RAW264.7 cell lines expressing an inducible miR-29
competitive inhibitor (sponge construct), miR-29 knock-down impaired osteoclastic
commitment and migration of pre-osteoclasts. However, miR-29 knock-down did not
affect cell viability, actin ring formation, or apoptosis in mature osteoclasts. To better
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understand how miR-29 regulates osteoclast function, we validated miR-29 target genes
using Luciferase-3’ UTR (untranslated region) reporter assays and specific miR-29
inhibitors. We demonstrated that miR-29 negatively regulates RNAs critical for
cytoskeletal organization, including Cell Division Control protein 42 (Cdc42) and SLITROBO Rho GTPase activating protein 2 (Srgap2). Moreover, miR-29 targets RNAs
associated with the macrophage lineage: G protein-coupled receptor 85 (Gpr85), Nuclear
Factor I/A (Nfia), and Cd93. In addition, Calcitonin receptor (Calcr), which regulates
osteoclast survival and resorption, is a novel miR-29 target. Thus, miR-29 is a positive
regulator of osteoclast formation, and targets RNAs important for cytoskeletal
organization, commitment, and osteoclast function. We hypothesize that miR-29 controls
the tempo and amplitude of osteoclast differentiation.

INTRODUCTION

Osteoclasts are the only cells able to resorb mineralized matrix. The activity of
these cells is critical for bone growth, normal bone remodeling, and fracture repair. A
fine balance between the number and activity of osteoblasts and osteoclasts is necessary
for bone homeostasis (2). Pathologies associated with abnormal osteoclast number or
function include osteopetrosis, osteoporosis, and inflammatory osteolysis. Osteopetrosis
is caused by impaired resorption, due to insufficient osteoclast formation or activity, and
results in augmented bone density. In this disorder, changes in bone morphology are
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often accompanied by immunodeficiency and anemia, due to narrowing of the bone
marrow cavity and reduced expansion of the hematopoietic cell populations (3, 4).
Osteoporosis is caused by excessive bone resorption coupled with insufficient bone
formation. Systemic loss of bone mass can be triggered and supported by hormonal
imbalance, such as estrogen deficiency. In inflammatory osteolysis, signaling from
immune cells in conditions such as rheumatoid arthritis and periodontal disease
determine bone loss localized at the joints or in the oral cavity. Thus, abnormal
osteoclastic activity can result in higher predisposition to fractures, impaired joint
mechanics, and loss of teeth (5).
The differentiation of osteoclasts from hematopoietic precursors is a complex
multistep process (2). It begins with the commitment of multipotent precursors to
differentiation along the osteoclast lineage. These committed monocytic cells
subsequently migrate and fuse together to form multinucleated mature osteoclasts (82).
Bone resorption is initiated when the osteoclast polarizes and organizes the cytoskeletal
structures that form the sealing zone and ruffled border. These dynamic structures, which
in vitro appear as an actin-rich ring, mediate the degradation of the bone surface, creating
an acidic environment and secreting proteolytic enzymes, to degrade the inorganic and
organic components of bone matrix, respectively (11). Tight control of the complex
osteoclast differentiation process is accomplished by the regulation of gene expression at
multiple transcriptional, post-transcriptional, and post-translational levels (83).
Substantial progress has been made in describing the mechanisms of M-CSF and
RANKL driven osteoclastogenesis and bone resorption, and key transcription factors
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involved include c-Fos, NFATc1, and NFĸB. In addition, several studies highlight the
role of post-translational modifications, mainly phosphorylation, in regulating the activity
of receptors and kinases important for transducing intracellular signals, such as the MCSF receptor (c-Fms), Src, and c-Jun N-terminus kinase (JNK) (12, 83). However, in the
last decade, the importance of an additional level of gene regulation has emerged: posttranscriptional control by microRNAs (miRNAs).
miRNAs are short sequences of non-coding, single-stranded RNA that can bind
target messenger RNAs (mRNAs) based on sequence complementarity. This process
involves the RNA-induced silencing complex (RISC), which, for the most part, mediates
the inhibition of gene expression by decreasing translation and/or by decreasing mRNA
stability (84). Often, miRNAs regulate biological functions by modulating the expression
of multiple genes that participate in the same or correlated pathways (85). miRNA levels
are rapidly altered during embryonic development, as well as in adulthood, resulting in
prompt and efficient post-transcriptional control (8, 86).
The overall importance of the miRNA processing pathway in the osteoclast
lineage was reported. In vitro silencing of key factors involved in miRNA processing,
including DiGeorge syndrome critical region 8 gene (DGCR8), Argonaute2 (Ago2), and
Dicer1, suppressed osteoclast differentiation and activity (53). In vivo, deletion of Dicer
in the monocyte/macrophage lineage, using a CD11b promoter driven-cre recombinase,
as well as in mature osteoclasts using a Cathepsin K promoter driven-cre, resulted in the
development of a mild osteopetrotic phenotype (53, 54).
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Recent studies identified specific miRNAs and miRNA targets involved in
osteoclast commitment and differentiation. For example, miR-223 promotes osteoclast
formation, at least in part, through the inhibition of NFIA (Nuclear factor 1/A) (53, 61).
Decreased NFIA expression is necessary for the terminal differentiation of osteoclasts
(53), as well as granulocytes and monocytes (68, 69). Further, miR-21 promotes
osteoclast differentiation, and it was shown to target PDCD4 (programmed cell death
domain 4). PDCD4 represses activator protein 1 (AP-1)-dependent transcription, and the
AP-1 family member c-Fos is essential for osteoclastogenesis (83). Therefore, by
suppressing AP-1 function, PDCD4 may exert a negative effect on osteoclast
differentiation. Another report demonstrated a negative effect of miR-155 on
osteoclastogenesis. miR-155 promotes the commitment of progenitor cells to the
macrophage

lineage,

through

repression

of

MITF

(microphthalmia-associated

transcription factor) (58). MITF is required in the later phases of osteoclast formation,
where it promotes the expression of genes crucial for osteoclast maturation and function,
like Trap, Oscar (osteoclast-associated immunoglobulin-like receptor), and Cathepsin K
(77).
We and others have studied the role of the miR-29 family in cells of the osteoblast
lineage. Although miR-29 family members target several critical extracellular matrix
mRNAs and limit their expression, this miRNA family promotes osteoblastic
differentiation, by targeting negative regulators of this process (87-89). We considered
that miR-29 family members may also play a role in osteoclastogenesis, given that altered
miR-29 levels were associated with hematopoietic malignancies. For example,
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diminished miR-29 levels were found in patients with chronic lymphocytic leukemia
(CLL), and correlate with advanced clinical features and poor prognosis in acute myeloid
leukemia (AML) (90-93).
In this study, we characterized the expression of miR-29 family members during
the differentiation of murine bone marrow-derived osteoclast cultures and an osteoclast
precursor cell line. We show that miR-29 is important for cell migration, osteoclast
commitment and differentiation, and we identified 6 novel miR-29 targets in osteoclastic
cells.

MATERIALS AND METHODS

Cell Culture.
Primary osteoclast precursor cultures were established from bone marrow of 6-8
week old C57BL/6 male mice, which had been depleted of B220/CD45R-positive and
CD3-positive cells (B and T lymphocytes, respectively). Briefly, bone marrow was
isolated from femurs, tibias, and humeri (94). Cells were incubated with Phycoerythrin
(PE)-conjugated primary antibodies for B220 and CD3 (eBioscience, San Diego, CA),
and with magnetically labeled anti-PE microbeads (Miltenyi Biotec, Auburn, CA).
Magnetic-Activated Cell Sorting (MACS®) Column Technology (Miltenyi Biotec,
Auburn, CA) was used to capture CD45R and CD3 positive cells in the column, and the
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flow-through

contained

a

population of cells enriched for the
monocytic and non-lymphoid lineage
cells (43). Flow cytometric analysis
confirmed that this procedure
depleted 93-95% of T and B cells,
thereby decreasing the heterogeneity of
the marrow cells that were subsequently
plated for experiments (Figure 3.1).
Cells were cultured in α-MEM (Gibco
Life Technologies, Grand Island, NY)
supplemented with 10% FBS (Fetal

Figure 3.1. Flow cytometric analysis of the
MACS sorted bone marrow cells.
Expression of the lymphocyte-specific
surface antigens CD45R and CD3 was
evaluated by flow cytometry. SSC (side
scattered light) is a measure of cell internal
complexity. Percentage of CD45R/CD3+
cells in the total population is indicated.

Bovine Serum, Atlas Biologicals, Fort
Collins, CO) and 30 ng/ml murine recombinant Macrophage Colony-Stimulating Factor
(M-CSF) (eBioscience, San Diego, CA). Bone marrow-derived osteoclast precursor cells
were plated in the presence of 30 ng/ml murine recombinant M-CSF and Receptor
activator of nuclear factor kappa-B ligand (RANKL) (eBioscience) for up to 5 days.
The mouse monocytic RAW264.7 (RAW) cell line was obtained from American
Type Culture Collection (ATCC, Manassas, VA) (TIB-71TM), and cultured in DMEM
(Gibco Life Technologies, Grand Island, NY) supplemented with 10% FBS. Cells were
cultured in α-MEM supplemented with 10% FBS and 30 ng/ml RANKL, to stimulate
osteoclastic differentiation.
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The human embryonic kidney (HEK293T) PhoenixTM-Eco cell line was a gift
from Nolan Lab, Stanford University, CA (95), and used for retrovirus production. These
cells were cultured in DMEM supplemented with 10% FBS. The HEK293FT cell line
was obtained from Invitrogen (Life Technologies, Grand Island, NY) and used for
lentivirus production. 293FT cells were cultured in DMEM supplemented with 10% FBS.

In Vitro Osteoclast Formation Assay.
Cells were fixed in 2.5% glutaraldehyde in PBS, and TRAP activity was detected
according to the manufacturer’s instructions, using the Acid Phosphatase Leukocyte
(TRAP) kit (Sigma-Aldrich). TRAP positive multinucleated cells containing more than
three nuclei were counted as osteoclasts under microscopic examination. Osteoclast area
was quantified using cellSens imaging software (Olympus, Center Valley, PA).

Quantitative Real time PCR.
Primary osteoclast precursors and RAW264.7 cells were plated at 53,000
cells/cm2. Total RNA was isolated from differentiating cultures using the miRNeasy Mini
kit (Qiagen, Valencia, CA). On-column DNase treatment was performed to reduce
contamination with genomic DNA, and an additional treatment with RQ1 DNase
(Promega, Madison, WI) was performed prior to gene expression analysis. miR-29
expression levels were analyzed with the TaqMan MicroRNA Assay (Life Technologies,
Grand Island, NY). According to the manufacturer’s instructions, 22.5 ng of RNA were
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reverse transcribed with specific
primers to generate cDNA. miR29 expression was detected by
qPCR in a MiQqPCR cycler (Bio-

Table 3.1. Primer sets for gene expression
analysis. The sequences of the primers used for
quantitative RT-PCR analysis are reported [primers
for HPRT, Cathepsin K, and TRAP as indicated in
(96)]
PRIMER NAME

SEQUENCE (5’ – 3’)

HPRT FW

gttggatatgcccttgactataatga

HPRT RV

caacatcaacaggactcctcgtatt

Cathepsin K FW

cgaaaagagcctagcgaaca

Cathepsin K RV

tgggtagcagcagaaacttg

To quantify mRNA levels

TRAP FW

cgtctctgcacagattgcat

in total RNA, DNased RNA was

TRAP RV

aagcgcaaacggtagtaagg

reverse-transcribed using Moloney

GFP FW

gtgagcaagggcgaggagctgttc

murine

GFP RV

gtaggtcagggtggtcacgaggg

and

F4/80 FW

tttcctcgcctgcttcttc

quantified by qPCR with iQ SYBR

F4/80 RV

ccccgtctctgtattcaacc

Green Supermix (Bio-Rad). The

Mac-1 FW

tcctgtttaatgactctgcgttt

primer sets used are shown in

Mac-1 RV

ggctccactttggtctctgt

Rad) and normalized to U6 small
nuclear RNA (RNUB6) levels
using the absolute quantification
method.

leukemia

transcriptase

virus-reverse

(Invitrogen),

Table 3.1. RNA levels were
determined using absolute quantification and normalized to hypoxanthine-guanine
phosphoribosyltransferase (HPRT) mRNA. RNA experiments were performed at least
twice, and each experiment contained biological triplicates. For qRT-PCR, each sample
was analyzed in duplicate.

39

Retroviral Constructs.
To obtain miR-29 knock-down, double-stranded oligonucleotides targeting the
miR-29a precursor were cloned into the retroviral vector pSilencer 5.1-H1 Retro
(Ambion). The sequences of the oligonucleotides used are indicated in Table 3.2. The
silencing construct was inserted into the pSilencer vector using BamHI and HindIII
restriction enzymes. As negative control, pSilencer 5.1 Retro Scrambled was used
(Ambion). Retrovirus was produced using the HEK293TPhoenixTM-Eco cell line (95).

miR-29 Knock-down and Osteoclast Formation.
Whole bone marrow was isolated from 6-8 week old C57BL/6 mice and plated
overnight on a tissue culture plastic plate to limit the amount of stromal cells. The nonadherent population of cells was centrifuged on a Ficoll gradient, to enrich for
macrophage precursors (97). These bone marrow-derived macrophages (BMMs) were
seeded at 5,000 cells/well in 96-well plates, in α-MEM supplemented with 10% FBS in
the presence of 30 ng/ml M-CSF. 48 hours after plating, cells were transfected with 50
nM anti-miRNA inhibitors (Dharmacon) using BioT reagent (Bioland Scientific,
Paramount, CA). Alternatively, cells were transduced with retroviruses harboring a miR29a knock-down construct or a scrambled control. Osteoclast differentiation was induced
with RANKL treatment (10 ng/ml), and osteoclast formation was evaluated by TRAP
staining.
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Table 3.2. PCR cloning primers. GenBank reference numbers for the genes of interest
are indicated. Restriction sites are underlined. MluI (FW) and HindIII (RV) restriction
enzymes were used for all the genes, with the exception of Cdc42-UTR, for which SacI
and MluI were used. In the oligonucleotides for miR-29 knock-down construct, BamHI
and HindIII sites are indicated.
RNA (MOUSE)

FW PRIMER (5’ – 3’)

RV PRIMER (5’ – 3’)

Calcr
(NM_007588.2)

ggatacgcgtatgtgaagccaccccaagca cggcaagcttcatgtacacagcagaagcgtttcaca
ttgtgatcc
c

Trap
(NM_001102405.1)

tctacgcgtagatggattcatgggtggtg

tttaagcttctggaacctcttgtcgctggc

Cathepsin K
(NM_007802.3)

tttacgcgtattccagccagccagcccatc

cgggccaagcttaaattgtaaatgagatactttatttca
aatacaaag

Srgap2
(NM_001081011.2)

tttacgcgtctgccctacatcctctctcc

tttaagcttaagggcatggtggtgcatgcttttaatttc

Cdc42-CDS
(NM_009861)

tctacgcgtgacaagatctaatttgaaatatta
tctaagcttagttggtacatattccgatggg
aaag

Cdc42-UTR
(NM_009861)

tttgagctcaaaggcctaaagaatgtgaaac tctacgcgtcatatacaaagagttgagacac

Gpr85
(NM_145066.4)

tttacgcgttgaggcgctgtttcagcac

cccaagcttcacataatacagttcaatgctagc

Cd93
(NM_010740.3)

tttacgcgttgtcccttaaacttgcaaaag

tttaagcttccttcccagaggcttactcg

Nfia
(NM_010905.3)

tttacgcgtaccatcctccagacagacca

cccaagcttcaggtgttgccatacatgtgt

miR-29a
knock-down

gatccgttcagagtcaatagaattctcaaga
gaaattctattgactctgaacttttttggaaa

agcttttccaaaaaagttcagagtcaatagaatttctct
tgagaattctattgactctgaacg

pSLIK Lentiviral Constructs.
To knock-down the activity of all miR-29 family members, we generated a miR29 “sponge”, which works as a competitive target for miR-29, relieving the repression of
its endogenous target mRNAs (Figure 3.5) (98). The murine osteonectin 3’ UTR contains
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a pair of miR-29 binding sites, within cDNA bases 1083 to 1149. 3 copies of this tandem
miR-29 binding site were cloned downstream of a GFP reporter gene, to generate the
miR-29 sponge. The GFP alone control or GFP_Sponge cDNAs were subcloned in the
pEN_Tmcs entry vector [plasmid 25751, Addgene, Cambridge, MA; (99)], which
contains a tetracycline inducible promoter (tetracycline responsive element, TRE). These
constructs were subjected to Gateway recombination with the lentiviral construct pSLIK,
harboring a hygromycin resistance selectable marker gene [plasmid 25737, Addgene;
(99)]. The Ubi-C (ubiquitin C) promoter in the pSLIK vector constitutively drives the
expression of the tetracycline activator (rtTA3), which, in the presence of doxycycline
(DOX), promotes the expression of the GFP or GFP_Sponge transgene from the TRE
promoter.

Lentivirus Production and Transduction.
pSLIK constructs containing GFP alone or GFP_Sponge genes were cotransfected in the HEK293FT cell line, along with the expression vectors for the viral
packaging proteins. These include the viral trans-activators Tat (pHDM-tat1b) and Rev
(pRC/CMV-rev1b), the viral core polyprotein and reverse transcriptase, encoded by the
GAG and POL genes respectively (pHDM-Hgpm2), and the VSV-G (vesicular stomatitis
virus) envelope glycoprotein (pHDM-G) (gift from the Lee lab, Harvard Gene Therapy
Initiative, MA). Culture medium containing the lentiviral particles was used to transduce
RAW264.7 cells. Pools of stably transduced cells were established by culture in the
presence of hygromycin (100 µg/ml).
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miR-29 Sponge Expression and Osteoclast Differentiation.
GFP and GFP_Sponge RAW264.7 cell lines were seeded at a cell density of
1,000 cells/well in 96-well plates, in DMEM supplemented with 10% FBS. 24 hours
later, osteoclast differentiation was stimulated by treatment with 30 ng/ml RANKL in αMEM supplemented with 10% FBS. The expression of the transgene was induced by
addition of 500 ng/ml doxycycline (DOX) to the culture medium (Sigma-Aldrich).
Osteoclast formation was evaluated by TRAP staining.

Cell Viability Assay.
GFP and GFP_Sponge RAW264.7 cells were plated in 96-well plates at 5,000
cells/well, in DMEM supplemented with 10% FBS. 24 hours later, cells were treated with
30 ng/ml RANKL, to induce osteoclastogenesis, in the presence or absence of 500 ng/ml
doxycycline, to activate transgene expression. Cell viability was assessed over 3 days by
MTS assay using the CellTiter 96 AQueous One Solution Cell Proliferation Assay kit, as
indicated by the manufacturer’s instructions (Promega).

Phagocytosis Assay.
GFP and GFP_Sponge RAW264.7 cells were cultured in α-MEM supplemented
with 10% FBS in the presence of 500 ng/ml of doxycycline and 30 ng/ml of RANKL for
24 hours prior to the assay. Cells were then plated at 100,000 cells/well in 96-well plates,
and allowed to adhere to the plate for 3 hours. Culture medium was replaced with a
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solution of pHrodo S. aureus bacterial particles (250 µg/ml), which will emit
fluorescence when phagocytosed (Life Technologies). Cells were incubated for 1 hour at
37ºC, and nuclei were stained with DAPI. Cultures were analyzed by fluorescence
microscopy. Phagocyotosis of pHrodo particles was quantified by measuring
fluorescence emitted at 590 nm, and normalized to DAPI fluorescence at 460 nm.

Macrophage Commitment Assay.
GFP and GFP_Sponge RAW264.7 cells were plated at 26,000 cells/cm2 in
DMEM supplemented with 10% FBS. Subsequently, cells were cultured in α-MEM
supplemented with 10% FBS in the presence of 500 ng/ml of doxycycline and 30 ng/ml
of RANKL for 24 hours. Total RNA was isolated from the cultures using the miRNeasy
Mini kit (Qiagen, Valencia, CA), and the expression of macrophage marker genes was
analyzed by qPCR as previously described. The primer sets used are shown in
Supplemental Table S1.

Cell Migration Assay.
GFP and GFP_Sponge RAW264.7 cells were cultured in DMEM, in the absence
of FBS, and in the presence of 500 ng/ml of DOX for 24 hours prior to the assay. Cells
were then plated at 200,000 cells/well on 8 µm pore polycarbonate membrane inserts in
6.5 mm Transwells (Corning, Tewksbury, MA). 30 ng/ml M-CSF was added to the
bottom chamber, as a chemotactic agent. Cells were incubated overnight, in the presence
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of DOX. Cells that did not migrate were removed from the top side of the transwell
membrane using a cotton swab. Upon fixation with 3.7% formaldehyde, cells on the
bottom side of the transwell membrane were stained with 0.05% Crystal violet solution.
Crystal violet stain was solubilized using 100% methanol, and optical density was
quantified at 540 nm.

Apoptosis Assay.
GFP and GFP_Sponge RAW264.7 were plated at 3,125 cells/cm2 in DMEM
supplemented with 10% FBS. 24 hours later, culture medium was switched to α-MEM
supplemented with 10% FBS, with the addition of 30 ng/ml of RANKL. After 2 days of
differentiation, expression of the transgene was induced with 500 ng/ml of DOX. 2 days
later, osteoclast apoptosis was assessed by Caspase-3 Colorimetric Assay Kit, as
indicated by the manufacturer’s instructions (GenScript, Piscataway, NJ).

Actin Ring Formation Assay.
GFP and GFP_Sponge RAW264.7 cells were seeded on glass chamber slides at
3,125 cells/cm2, in DMEM supplemented with 10% FBS. 24 hours later, culture medium
was switched to α-MEM supplemented with 10% FBS, with the addition of 30 ng/ml of
RANKL and 500 ng/ml of doxycycline. End point cultures were fixed with 3.7%
formaldehyde and F-actin was labeled with Rhodamine Phalloidin conjugate (Life
Technologies). Nuclei were visualized by using mounting medium containing DAPI
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(4',6-Diamidino-2-Phenylindole) (Invitrogen, Life Technologies). Cultures were analyzed
by fluorescent microscopy.

Luciferase Constructs.
Gene-specific PCR primers were used to amplify from mouse genomic DNA
template the coding sequences (CDS) or untranslated regions (UTRs) for Calcitonin
Receptor, Tartrate resistant acid phosphatase (Trap), Cathepsin K, Cdc42, Srgap2,
Gpr85, Cd93, and Nfia, which contained potential miR-29 binding sites (primer
sequences are reported in Table 3.2). Using the appropriate restriction enzymes, these
fragments were cloned downstream from Luciferase, in the Cytomegalovirus promoterdriven

Luciferase

reporter

vector

pMIR-REPORT
(Ambion,
TX).

Austin,

Site-directed

mutagenesis,

to

delete putative miR29 binding sites in
selected

constructs,

was performed by
overlap

extension

Table 3.3. Primer sets for site-directed mutagenesis of miR29 targets. Forward primers were designed to delete miR-29
binding sites (see Table 3.4), and used in combination with
complementary reverse primers.
RNA (MOUSE)

FW MUTAGENESIS PRIMER (5’ – 3’)

Calcr (site 2565)

gtttataaagcagatctagcagtaagagaa

Cdc42-CDS

aattaagtgtgttgttggtaaaacatgtct

Srgap2

ccccagctctgggagctgacgcctgtgaga

Gpr85

gtgggtgaacactagagtatcagtgctaaa

Cd93 (site 4403)

agccaatggagccactattttcacatatat

Nfia (site 2125)

ttttaatactttagggaaatggttgggctg
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(primer sequences are reported in Table 3.3). Luciferase plasmids containing the regions
of interest were used as templates for mutagenesis. All constructs were verified by
sequencing.

Luciferase Activity Assay.
RAW264.7 cells were plated at 58,000 cells/cm2. After 24 hours, cells were cotransfected with Luciferase constructs and a constitutively expressing β-Galactosidase
construct, as a control vector for transfection efficiency (GenBank accession number
U02451) (Clontech, Mountain View, CA) using BioT (BioT:DNA ratio 1.5 μl:1 μg). In
selected experiments, 50 nM anti-miR-29-a or -c or negative control (scrambled) miRNA
inhibitors were also transfected. 6 hours post-transfection, cells were treated with or
without RANKL (30 ng/ml) in α-MEM supplemented with 10% FBS. Following 48
hours, cell lysates were harvested using Reporter Lysis Buffer (Promega). Samples were
analyzed for Luciferase activity using Luciferase Assay System (Promega), and
normalized to β-Galactosidase activity, which was assessed using Galacton® reagent
(Applied Biosystem, Foster City, CA). Each Luciferase experiment was performed at
least three times, using n=6.
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Table 3.4. Potential miR-29 binding sites in genes important for the
macrophage/osteoclast lineage. Putative miR-29 sites were identified using miRanda,
DIANA-mirExTra, PicTar, and RNAhybrid. miR-29 family members have identical seed
binding (miRNA bases 2-8), and the sequence for miR-29a is shown in the table. The
position of the miR-29 site in the target mRNA sequence is indicated. The miR-29 sites
mutated using the primers reported in Table 3.3 are indicated (±).
RNA
miR-29 site
Sequence
Calcr

2095

Calcr

2565(±)

Trap

133

Ctsk

9764

Cdc42

166(±)

Cdc42

683

Cdc42

1281

Cdc42

1686

Srgap2

6093(±)

Gpr85

2498(±)

Cd93

2421

Cd93

4403(±)

Cd93

5279

Nfia

2125(±)

Nfia

3056

Nfia

7184

3' UUGGCUAAAGUCUA----CCACGAU 5’ miRNA
:||| | |||||||
||||||
5' GACCUAGUUCAGAUACAGGGUGCUCC 3’ RNA
3' UUGGCUAAAGUCUA-CCACGAU 5’
miRNA
||| || |
| |||||||
5' UACCUCUUGCCCUUGGGUGCUAU 3’
RNA
3’ AUUGGCUAAAGU--CUACCACGAU 5’
miRNA
| ||| |||
|||||||
5’ AGAUGGAU-UCAUGGGUGGUGCUGC 3’ RNA
3' AUUGGCUAAAGUCUACCACGAU 5’ miRNA
| || | |||||||
5' UUUCUCCUCUC-GUUGGUGCUU 3’ RNA
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA
: |:|
|||||||||:
5' UGUUGGU----GAUGGUGCUGU 3' RNA
3' AUUGGCUAAA-------GUCUAC-CACGAU 5' miRNA
||||||
|||:|| |||||:
5' GAACCGAAGAAGAGCCGCAGGUGUGUGCUGC 3' RNA
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA
|
|
|| |||||||
5' AACGUGUCCCCACCUGGUGCUC 3' RNA
3' UUGG-CUA--------AAG------UCUACCACGAU 5' miRNA
:||| |:|
|||
:|||||||:||
5' GACCUGGUACCUAGGGUUCCUAACGGGAUGGUGUUA 3' RNA
3’
UGGCUAAAGUCU-----ACCACGAU 5’ miRNA
| | |||
|||||||
5’ CCUAGCUGUCUUCCUUAUCUCUGGUGCUU 3’ RNA
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA
| |||
|| |||||||
5' AUAACGAAAGUAGCAGGUGCUA 3' RNA
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA
| || ||
|||||||||
5' CGAAGGAGUU--ACUGGUGCUA 3'RNA
3' AUUGGCUAAAGUCUA-CCACGAU 5' miRNA
| ||:| | :| || ||||||
5' UCACUGUUCCUAAAUGGGUGCUU 3' RNA
3' AUUGGCUAAAGUCUACCACGAU 5' miRNA
| | |
| | |||||||
5' UCAUCACCAGCUCAGGGUGCUA 3' RNA
3’ UGGC-----UAAAGUCUACCACGAU 5’ miR-29
||:|
||||| ||||||||:
5’ GACUGUCGUAAUUUCUCAUGGUGCUG 3’ RNA
3’ UGGCUAAAGUCUACCACGAU 5’ miRNA
|| ||||||||
5’
AUCUAAUGGUGCUU 3’ RNA
3’ UGGC-----UAAAGUCUACCACGAU 5’ miRNA
||:|
||||| ||||||||:
5’ GACUGUCGUAAUUUCUCAUGGUGCUG 3’ RNA
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Data Analysis.
Data are presented as mean ± SEM. Data were analyzed by Student’s t test or
one-way ANOVA with Bonferroni post-hoc test as appropriate (KaleidaGraph, Synergy
Software, Reading, PA.

RESULTS

miR-29 expression increases during in vitro osteoclast differentiation.
We analyzed the expression of miR-29 family members in mouse bone marrow
depleted of B220 and CD3 positive cells, and cultured in the presence of M-CSF and
RANKL for up to 5 days. In these cultures, osteoclasts were evident by day 3, and
osteoclast number and size where highest at day 5 (Figure 3.2B, C, and D). qRT-PCR
showed that all the miR-29 family members, miR-29a, -b, and -c, were expressed at a
similar level, and that their expression was not increased until between days 3 and 5 of
differentiation (Figure 3.2A). In contrast, mRNA levels for the osteoclast markers TRAP
and Cathepsin K were increased from day 1 to day 3, and sustained at day 5 (Figure
3.2E). RANK expression was already elevated at day 1, and maintained during the course
of osteoclast differentiation, whereas NFATc1 levels peaked at day 3, and then decreased
(Figure 3.2F).
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Figure 3.2. miR-29 increases during osteoclast differentiation in vitro. Primary
bone marrow osteoclast precursors depleted of B and T cells were differentiated by
culturing with 30 ng/ml, each, M-CSF and RANKL. A, miR-29a, -b, and -c expression
was quantified after 1, 3, and 5 days of culture and normalized to U6 (n=4). B, Number
of TRAP(+) osteoclasts per well (n=3, 96 well plate). C, Osteoclast area: boxplot lines
represent the 25% quartile of the data, the median, and the 75% quartile. Outliers are
denoted by dots. (n=3 wells, 96 well plate). D, Representative images of TRAP stained
cultures after 1, 3, and 5 days of differentiation were captured using 10X magnification.
E, F, Osteoclast marker mRNAs were quantified by qRT-PCR and normalized to
HPRT (n=4). * significantly different from day 1, p<0.05.
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Table 3.5. miR-29 knock-down decreases osteoclast formation in vitro. Mature
sequence of the non-targeting scrambled control (cel-miR-67) and the miR-29 family
members is indicated. Divergent bases are underlined. Seed binding region (bases 2-8) is
in italic. Primary BMMs were transfected with 50 nM anti-miR-29a, -b, or -c inhibitor or
non-targeting scrambled control oligonucleotides. Cells were treated for 3 to 6 days with
M-CSF (30 ng/ml) and RANKL (10 ng/ml). Osteoclast formation was evaluated by
TRAP staining (n=4 wells, 96 well plate). * significantly different from 29a, -b, or -c
inhibitor, p<0.01.
Inhibitor

Mature miRNA sequence

Day 3

Day 4

Day 5

Day 6

Scrambled

ucacaaccuccuagaaagaguaga

5.2 ± 1.6*

21.6 ± 6.3*

46.0 ± 4.3*

203.8 ± 17.9*

miR-29a

uagcaccaucugaaaucgguua

0

0

11.0 ± 1.7

17.3 ± 1.4

miR-29b

uagcaccauuugaaaucgguua

0.7 ± 0.5

2.8 ± 1.0

10.2 ± 1.9

17.8 ± 1.9

miR-29c

uagcaccauuugaaaucaguguu

0

0

6.5 ± 2.3

17.8 ± 2.1

miR-29 is a positive regulator of osteoclastogenesis.
To investigate the role of miR-29 in osteoclast differentiation, we inhibited miR29 activity in primary cultures of bone marrow-derived macrophage/osteoclast precursors
(BMMs), using transiently transfected miR-29a, -b, or -c specific oligonucleotide
inhibitors. Throughout the time course analyzed, miR-29 inhibition resulted in a
significant reduction in the number of TRAP positive multinucleated osteoclasts
compared to the scrambled, non-targeting control (Table 3.5; Figure 3.3A). These data
suggest that miR-29 inhibition does not merely delay osteoclastogenesis, and that miR-29
activity is important for osteoclast formation. Consistent with these data, primary bone
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marrow-derived precursors transduced with a retrovirus expressing a miR-29a inhibitor
also showed decreased osteoclast formation compared with control (Figure 3.3B).
miR-29 family members have identical seed binding regions (miRNA bases 2-8).
miR-29a and -29c differ by only one base, whereas miR-29b is more divergent. In the
transient transfection studies shown in Table 1, the miR-29b inhibitor appeared to be
somewhat less efficacious at the early time points, days 3 and 4. However, the isoformspecific inhibitors had similar effects at the later time points, days 5 and 6. Overall, the
miR-29 isoform inhibitors had similar activity. Given the degree of conservation among
the miR-29 isoforms, it may be difficult to tease out isoform-specific effects using an
inhibitor strategy.
When BMMs were plated at a higher density, the formation of large osteoclasts
(>8 nuclei) was significantly diminished in cells transiently transfected with miR-29c
inhibitor [large osteoclast number (per well) in scrambled 108±5 versus miR-29a
inhibitor 74±3, p<0.01]. This indicates that miR-29 knock-down negatively affects
osteoclast size, suggesting that miR-29 activity plays a positive role in osteoclast
maturation (Figure 3.3).
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The

primary

cultures

obtained

bone

marrow

from
are

heterogeneous, even when
depleted of lymphocytes
(97). For this reason, we
sought a more simplified
and homogeneous model
system for the purpose of
evaluating the mechanisms
by which miR-29 regulates
osteoclast

differentiation.

Therefore, we chose to use
the monocytic cell line
RAW264.7.

We

first

characterized
expression

the
of

miR-29

family members in these
cells after treatment with
RANKL for up to 4 days.
We found that expression
of all miR-29 family

Figure 3.3. Inhibition of miR-29 represses osteoclast
formation in vitro. A, BMMs were transiently transfected
with a miR-29a inhibitor and differentiated for 3 days with
M-CSF (30 ng/ml) and RANKL (10 ng/ml).
Representative images of the cultures were captured using
10X magnification. B, BMMs were transduced with
pSilencer retrovirus for miR-29a knock-down or a nontargeting scrambled control, and differentiated for 3 days.
Osteoclast formation was evaluated by TRAP staining
(n=6 wells, 96 well plate). * significantly different from
scrambled, p<0.05.
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Figure 3.4. miR-29 expression in RAW264.7 cells recapitulates the pattern
observed in primary osteoclast precursor cells. A, The expression of miR-29a, -b,
and -c was analyzed over 4 days of differentiation with RANKL (30 ng/ml). B, Number
of osteoclasts per well (n=3, 96 well plate). C, Osteoclast area: boxplot lines represent
the 25% quartile of the data, the median, and the 75% quartile. Outliers are denoted by
dots. (n=3 wells, 96 well plate). D, Representative images of TRAP stained cultures at
days 0, 1, 2, 3, and 4 of differentiation, respectively, were captured using 10X
magnification. E, F, Gene expression levels for osteoclast markers. * significantly
different from day 0, p<0.05.
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members was modestly, but significantly decreased after 24 hours of RANKL treatment
(Figure 3.4A). Levels of miR-29a, -b, and -c then increased as osteoclastogenesis
progressed, in a trend similar to that observed in the primary cultures (compare with
Figure 3.2A). In these cultures, osteoclast number and size peaked on day 3, and were
decreased on day 4 due to apoptosis of mature osteoclasts (Figure 3.4B-D). As observed
in the primary cells, the osteoclast marker genes, Trap and Cathepsin K, also increased
with osteoclastic differentiation (Figure 3.4E). In contrast, RANK was highly expressed
throughout the time course analyzed, and NFATc1 increased at day 1 of RANKLtreatment and was subsequently down-regulated (Figure 3.4F). These data suggested that
RAW264.7 cells could be a valid surrogate for analyzing the mechanisms by which miR29 regulates osteoclastogenesis.

Inhibition of miR-29 activity impairs osteoclastic differentiation of RAW264.7.
To further define the activity of miR-29 in osteoclastogenesis, we developed an
inducible lentiviral knock-down construct, based on the miRNA “sponge” strategy (98).
The miR-29 sponge consisted of 6 miR-29 binding sites cloned downstream of GFP, in a
DOX-inducible lentiviral vector (Figure 3.5A). Expression of the GFP_Sponge RNA can
work as a decoy or competitive inhibitor for all the members of the miR-29 family, which
share sequence identity in the seed region (nucleotides 2-8 of the miRNA sequence).
RAW264.7 cells were stably transduced with lentivirus harboring the miR-29 “sponge”
(GFP_Sponge cells) or GFP alone (GFP cells).
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Figure 3.5. miR-29 knock-down inhibits osteoclastic differentiation of RAW264.7
cells. A, Schematic representation of doxycycline (DOX)-inducible GFP and
GFP_Sponge constructs. TRE, tetracycline responsive element. B, GFP RAW264.7 cell
line was treated for 24 hours with increasing concentrations of DOX. GFP mRNA
expression was quantified by qRT-PCR and normalized to HPRT. C, GFP and
GFP_Sponge RAW264.7 cells were treated with 500 ng/ml of DOX. After 2 and 3 days
of differentiation with RANKL (30 ng/ml), osteoclast formation was evaluated by
TRAP staining (n=6, 96 well plate). * significantly different from GFP, p<0.05.
To confirm DOX-inducible expression of the transgene, we quantified GFP
mRNA levels in GFP cells treated for 24 hours with different doses of DOX. qRT-PCR
verified that GFP RNA was induced in a dose-responsive fashion, in the presence of
increasing concentrations of DOX (Figure 3.5B). The 500 ng/ml dose of doxycycline was
chosen for the subsequent assays because it produced a level of transgene expression
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similar to that of TRAP mRNA, while representing a DOX dose well below that recently
reported to decrease osteoclast differentiation in bone marrow cells in vitro (100).
We used the GFP_Sponge RAW264.7 cells as a relatively homogeneous cell
population to study the mechanisms by which miR-29 regulates osteoclastogenesis. In
cells treated with DOX and RANKL, we observed reduced formation of TRAP-positive
multinucleated cells in the GFP_Sponge
cultures after 2 days, in comparison with the
cells expressing the GFP transgene only
(Figure 3.5C). After 3 days, this disparity
was even more pronounced, as the formation
of TRAP-positive multinucleated cells was
increased only in the GFP RAW264.7
cultures. There was no difference in the
ability of GFP and GFP_Sponge cells to
form TRAP-positive multinucleated cells in
the absence of DOX (data not shown). These
results confirm the positive role of miR-29 in
osteoclastogenesis, as observed in primary
cells (Table 3.5; Figure 3.3).
To determine whether miR-29 knockdown in the GFP_Sponge cultures impaired
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Figure 3.6. Inhibition of miR-29 does
not affect cell viability. GFP and
GFP_Sponge RAW264.7 cells were
treated with RANKL (30 ng/ml) in the
presence or absence of DOX (500
ng/ml). Cell viability was measured over
3 days by MTS assay (n=6). Growth
curves in the presence or absence of
DOX were superimposable. The lines
without symbols illustrate linear growth
curves with similar slopes.

osteoclast formation due to altered cell proliferation or viability, GFP or GFP_Sponge
cells were cultured in the presence or absence of DOX for up to 3 days. Viable cells were
quantified by MTS assay. All cultures displayed similar growth curves, suggesting that
miR-29 did not promote osteoclast formation by regulating cell growth (Figure 3.6).

Inhibition of miR-29 activity impairs RAW264.7 cell commitment to the osteoclast
lineage.
Some miRNAs regulate differentiation by promoting commitment to one cell fate
at the expense of another. Since RAW264.7 cells have the potential to differentiate into
osteoclasts or macrophages, we evaluated the effect of miR-29 knock-down on their
lineage commitment. RAW264.7 cells have phagocytic properties, which are increased
when committed to the macrophage fate. Therefore, we quantified phagocytosis in GFP
and GFP_Sponge cells that had been induced toward osteoclastic differentiation by
culture in the presence of RANKL for 24 hours. Phagocytosis was not altered in the GFP
cells treated with DOX. However, when miR-29 activity was knocked-down in
GFP_Sponge cultures treated with DOX, we observed increased phagocytic activity
(Figure 3.7A, B). In addition, we analyzed the expression of genes associated with
macrophage and osteoclast differentiation. DOX treatment of GFP_Sponge cells
increased mRNA for macrophage markers F4/80 and Mac-1, and decreased mRNA for
the early osteoclast marker NFATc1. In contrast, mRNA for the more mature osteoclast
marker, Cathepsin K, was not affected (Figure 3.7C, D). These data suggest that miR-29
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knock-down promotes the commitment of the RAW264.7 cell line to the macrophage
lineage, at the expense of osteoclastogenesis.

Figure 3.7. miR-29 knock-down supports RAW264.7 cell commitment to the
macrophage lineage. GFP and GFP_Sponge RAW264.7 cells were induced toward
osteoclastic differentiation by 24 hours RANKL treatment (30 ng/ml) in the presence or
absence of DOX (500 ng/ml). A, Lineage commitment was assessed by phagocytosis
assay. Cells were incubated for 1 hour with pHrodo bacterial particles (250 µg/ml).
Cells that have phagocytosed the particles display red fluorescence (arrowheads).
Nuclei were stained using DAPI reagent. Representative images of the cultures were
captured using 10X magnification. Scale bar, 100 µm. B, Phagocytosis was quantified
by measuring rhodamine fluorescence and normalized to DAPI fluorescence (n=6). C,
Macrophage marker mRNAs, and D, osteoclast marker mRNAs were quantified by
qRT-PCR and normalized to HPRT (n=3). * significantly different from no DOX,
p<0.05.
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Inhibition of miR-29 activity impairs RAW264.7 migration.
In order to form osteoclasts, the migration of precursor cells is critical. We
analyzed the ability of GFP and GFP_Sponge cells to migrate in response to a
chemotactic stimulus using a modified Boyden Chamber (Transwell) assay. We found
that GFP-expressing RAW264.7 cells displayed robust migration toward M-CSF
supplemented culture medium (Figure 3.8). However, expression of the miR-29 sponge
completely abrogated the capability of these osteoclast precursor cells to respond to the
chemotactic agent, strongly indicating that miR-29 expression supports cell migration
(Figure 3.8).

Figure 3.8. miR-29 promotes the migration of RAW264.7 cells. A, GFP and
GFP_Sponge cells were cultured for 24 hours with DOX (500 ng/ml). Cells were
plated on transwells with 8-µm pores and allowed to migrate overnight toward M-CSF
(30 ng/ml). The cells that migrated through the membrane were stained with crystal
violet. B, Crystal violet staining was quantified. * significantly different from no MCSF, p<0.05, n=6.
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Figure 3.9. Inhibition of miR-29 does not affect apoptosis of mature osteoclasts, or
actin ring formation. A, GFP and GFP_Sponge RAW264.7 cells were differentiated for
2 days with RANKL (30 ng/ml). The expression of the transgene was induced by
addition of DOX (500 ng/ml) at day 3. Caspase-3 activity in mature osteoclast cultures
was quantified after 4 days of differentiation (n=6). C, GFP and GFP_Sponge
RAW264.7 cells were cultured on glass chamber slides for 4 days in the presence of
DOX (500 ng/ml) and RANKL (30 ng/ml). Actin ring formation was evaluated by
phalloidin staining (red), and nuclei were visualized with DAPI reagent (blue).
Representative images were captured using 5X magnification. Boxed regions i and ii
were visualized at 20X magnification. Actin rings are indicated by arrows. Scale bar, 100
µm.
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Figure 3.10. Luciferase analysis of miR-29 targets. Potential miR-29 targets were
identified using a bioinformatic approach. Putative miR-29 binding sites (arrow heads)
are present in the coding sequence and/or in the 3’UTR. The corresponding regions
(between the vertical lines) were cloned into the pMIR-REPORT Luciferase vector,
downstream of the Luciferase gene. The “±” symbol denotes the binding site deleted for
the constructs shown in Figure 9. A, Putative miR-29 binding sites were identified in
genes important for osteoclastogenesis. B, Luciferase activity was quantified in
RAW264.7 cells co-transfected with a miR-29c inhibitor or a scrambled non-targeting
control, and normalized to β-Galactosidase activity. Cells were treated with RANKL (30
ng/ml) for 48 hours after transfection. C, Putative miR-29 binding sites were identified in
genes important for cytoskeletal remodeling and cell migration. D, Luciferase activity. E,
Potential miR-29 target genes associated with the macrophage lineage. F, Luciferase
activity.* significantly different from scrambled, p<0.05, n=6.
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Inhibition of miR-29 activity does not affect the apoptosis of mature osteoclasts or
actin ring formation.
Osteoclasts are terminally differentiated cells, and their ultimate fate is to undergo
apoptosis (i.e. Figure 3.4B). It is possible that increased apoptosis could contribute to the
decrease in number and size of osteoclastic cells observed in the presence of the miR-29
sponge. Therefore, we analyzed Caspase-3 activity in GFP and GFP_Sponge cells
cultured for 4 days in the presence of RANKL. The miR-29 sponge was only expressed
during days 3 and 4 of culture, to allow initiation of osteoclastic differentiation. We did
not detect a significant difference in Caspase-3 activity in cells expressing the miR-29
sponge, compared with the other groups (Figure 3.9A). This suggests that miR-29 knockdown does not affect the survival of mature osteoclasts.
The formation of actin rings is a critical step for osteoclast-mediated bone
resorption. To determine whether miR-29 knock-down affects actin ring formation, the
GFP and GFP_Sponge were cultured for 4 days in the presence of RANKL and subjected
to phalloidin staining. Although fewer and smaller multinucleated TRAP-positive cells
were identified in miR-29 sponge cultures, their actin ring structures were intact (Figure
3.9B panels i, ii).

miR-29 targets RNAs important for the macrophage/osteoclast lineage.
Our functional assays indicated that miR-29 is important for osteoclastogenesis,
and promotes cell migration and osteoclast commitment. To better understand the
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underlying mechanisms, we focused on identifying the mRNAs that are targeted by miR29 and whose functions are important in the macrophage/osteoclast lineage. We analyzed
a list of genes expressed in osteoclastic cells (S-K Lee, unpublished data) for potential
miR-29 targets, using several different algorithms for miRNA target prediction
(miRanda, DIANA-mirExTra, PicTar, RNAhybrid). The list of potential targets was
refined based on the ability of the miRNA to base pair with the target mRNA. We chose
to clone and analyze 8 candidate genes with a well documented role in osteoclasts (Figure
3.10A), or with a role in cell migration (Figure 3.10C), or with a role in the macrophage
lineage (Figure 3.10E) (Tables 3.2, 3.4).
We cloned the sequences containing the potential binding sites for miR-29 into a
Luciferase reporter vector. Most constructs contained regions of interest ≥1 kb in length
(Figure 3.10A, C, E). In these constructs, luciferase expression was driven by a strong,
constitutive promoter, with the cloned regions serving as 3’ UTR for the Luciferase gene.
Therefore, luciferase activity represents the regulatory activity of the sequence of interest.
RAW264.7 cells were transiently transfected with the luciferase reporter plasmids and
miR-29c inhibitor oligonucleotides. Increased luciferase activity in the presence of the
miR-29 inhibitor would suggest that miR-29 targets that RNA region.
Of the RNAs with a well known function in osteoclastic cells, Calcitonin receptor
(Calcr, Ctr), Trap, and Cathepsin K (Ctsk, Catk) had potential miR-29 binding sites. The
potential miR-29 binding site in the Trap RNA was in the coding region, while those for
Calcr and Ctsk were in the 3’ UTR. There were 2 potential miR-29 binding sites in the
Calcr 3’ UTR. miR-29c inhibitor only increased luciferase activity from the construct
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containing the Calcr 3’ UTR, suggesting that Calcr RNA is targeted by miR-29, whereas
Trap and Ctsk are not (Figure 3.10B). The potential miR-29 binding site at base 2565 in
the Calcr 3’ UTR had the most complementarity to miR-29 family members. When we
deleted this miR-29 binding site, the ability of the miR-29 inhibitor to increase luciferase
activity was lost, indicating that this sequence is specific for miR-29-mediated regulation
(Figure 3.11A).

Figure 3.11. Deletion mutants of miR-29 binding sites. Putative miR-29 binding sites
(marked with “±” in Figure 3.10) in the miR-29 target genes were deleted from pMIRREPORT Luciferase vectors. Luciferase activity was quantified in the RAW264.7 cells
co-transfected with a miR-29c inhibitor or a scrambled non-targeting control, and
normalized to β-Galactosidase activity. Cells were treated with RANKL (30 ng/ml) for
48 hours after transfection. * significantly different from scrambled, # significantly
different from 29c inhibitor in the wild type vector, p<0.05, n=6.
For RNAs important for cytoskeletal organization, we analyzed Cell Division
Control protein 42 (Cdc42) and SLIT-ROBO Rho GTPase activating protein 2 (Srgap2)
(Figure 3.10C). Cdc42 is important for osteoclast function and migration and srGAP2
participates in the same signaling pathway as Cdc42 (35). Although expressed in
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osteoclasts, srGAP2 has not been studied in the osteoclast lineage. There were potential
miR-29 binding sites in the coding region and in the 3’ UTR of Cdc42, and the miR-29
inhibitor increased luciferase activity
from constructs containing either
region, as well as the construct
carrying the Srgap2 3’ UTR (Figure
3.10D). Deletion of the potential
miR-29 binding site in the coding
region of Cdc42 abolished the ability
of the miR-29c inhibitor to relieve
repression of luciferase activity,
indicating that this is a miR-29
binding

site

(Figure

3.11B).

Similarly, deletion of the potential
miR-29 binding site in the Srgap2 3’
UTR

construct

abrogated

the

response of the construct to miR-29c
inhibitor, indicating that the Srgap2
3’ UTR is targeted by miR-29
(Figure

3.11C).

Deletion

mutagenesis was not performed on
the mouse Cdc42 3’ UTR construct

Figure 3.12. Luciferase analysis of miR-29
targets in the absence of RANKL. The
luciferase constructs depicted in Figure 8 were
co-transfected in RAW264.7 cells with a miR29c inhibitor or a scrambled control. Luciferase
activity was quantified and normalized to βGalactosidase activity. * significantly different
from scrambled, p<0.05, n=6.
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because functional miR-29 binding sites in the human 3’ UTR were previously reported
(101).
With regard to genes associated with the macrophage lineage, we chose to
examine G protein-coupled receptor 85 (Gpr85), Nuclear Factor I/A (Nfia), and Cd93
(Figure 3.10E). NFIA expression inhibits both macrophage and osteoclast maturation,
whereas GPR85 and CD93 are expressed during macrophage differentiation (53, 69, 102,
103). Nfia and Cd93 had each 2 potential miR-29 binding sites in the 3’ UTR segment
analyzed, while Gpr85 had one site. The miR-29c inhibitor increased luciferase activity
for Gpr85, Cd93, and Nfia constructs, suggesting that these UTRs are miR-29 targets
(Figure 3.10F). Deletion of the potential miR-29 binding site in the Gpr85 3’ UTR
eliminated the miR-29c inhibitor-mediated increase in luciferase activity, indicating that
this site is directly regulated by miR-29 (Figure 3.11D). For Cd93 (C1qRp), we deleted
the potential miR-29 binding site at base 4403, and for Nfia, we deleted the miR-29 site at
2125. These sites were chosen because, of the 2 present in the UTR construct, they had
the most complementarity to miR-29 family members. The ability of the miR-29c
inhibitor to relieve repression of luciferase activity in the Cd93 and Nfia mutant
constructs was significantly decreased, but not totally abolished, likely due to the
remaining functional miR-29 binding site in the construct (Figure 3.11E, F) (Table 3.4).
It should be noted that the transfection studies shown in Figure 10 were
performed in cells treated with RANKL, and similar trends were also noted in the
absence of RANKL (Figure 3.12). Moreover, similar results were obtained when miR29a inhibitor was used instead of miR-29c inhibitor (data not shown). Overall, miR-29
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may promote osteoclastogenesis by repressing RNAs important for differentiation to the
alternative macrophage lineage. miR-29 targeting of RNAs important for osteoclast
function and actin remodeling may allow subtle regulation of the rate of osteoclast
differentiation (Table 3.6).

DISCUSSION

Osteoclast commitment and maturation is an intricate, multi-step process,
modulated by the combined activity of numerous signaling pathways. Since miRNAs can
control the expression of several genes working in one or multiple pathways, it is likely
that miRNAs orchestrate many of the changes in gene expression or activity necessary
for osteoclast differentiation. In this study, we demonstrate that miR-29 plays a positive
role in osteoclastogenesis. Its expression increases during differentiation, and miR-29
knock-down impairs migration, commitment, and osteoclastogenesis. Our study is unique
in that we validated a set of 6 novel miR-29 targets, which will contribute to our
understanding of miR-29 function in osteoclasts and in other cell types (Table 3.6).
The miR-29 family consists of four genes that encode 3 mature miRNAs. These
genes are organized in genomic clusters: miR-29a and miR-29b-1 are transcribed as a
single polycistronic primary transcript from mouse chromosome 6, and miR-29b-2 and
miR-29c are also transcribed as a polycistronic transcript from chromosome 1 (104, 105).
The three mature miRNAs of this family, miR-29a, -b, and -c, present high sequence
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conservation and genomic organization in mouse, rat, and human, and nucleotides in
positions 2-8, seed bases which are important for target recognition and binding, are
identical (Table 3.5) (106). Although miR-29 family members may have overlapping
targets, the mature miR-29 family members can be expressed at different levels,
suggesting distinct transcriptional or post-transcriptional regulation of these genes (107,
108).
The expression of miR-29 family members increased during the osteoclast
differentiation process, in both primary cultures and in RAW264.7 cells, and miR-29
knock-down decreased osteoclast formation, suggesting that this miRNA family plays a
positive role in differentiation. Studies from our laboratory and others demonstrate a
positive role of miR-29 in the differentiation of other lineages, including osteoblastic and
myogenic (87, 89, 109, 110). More recently, miR-29 was identified as one of 7 miRNAs
that, in concert, can restrict proliferation and promote differentiation (111). Thus, the
increase in miR-29 expression seen in the later stages of osteoclast differentiation may be
in response to RANKL-induced differentiation program and withdrawal from the cell
cycle.
The Calcr 3’ UTR is targeted by miR-29, and CTR plays an important role in
osteoclast function and cell survival. CTR is a G protein-coupled receptor that mediates
the anti-apoptotic effect of calcitonin on mature osteoclasts, while inhibiting their
resorption activity (112). Thus, the targeting of Calcr by miR-29 in mature osteoclasts
could promote resorption.
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Table 3.6. Newly validated miR-29 targets and their biology.
GENE

BIOLOGY

Calcr, Ctr
Calcitonin receptor

Calcitonin decreases resorption and increases OC
survival (112).

Cdc42
Cell division cycle 42

Promotes OC survival and differentiation.
Regulates rate of actin ring formation (113).

Srgap2
SLIT-ROBO Rho GTPase
activator protein

Induces membrane protrusions.
Knock-down reduces cell adhesion and increases
migration (114, 115).

Gpr85
G protein-coupled receptor
85

Transiently induced by LPS in macrophages (103,
116).

Cd93
complement component 1q
receptor 1

Promotes differentiation of monocytes into
macrophages (102).

Nfia
nuclear factor I/A

Negatively controls c-Fms.
Over-expression inhibits osteoclast formation.
Increased in Dicer-/- null osteoclast precursors (53, 69).

We identified 3 new miR-29 targets that may be involved in commitment of
precursor cells to the osteoclast lineage: Nfia, Cd93, and Gpr85 (Figures 3.10 and 3.11,
Table 3.6). Transcript levels for these genes are decreased in primary cultures of
osteoclast progenitors treated for 4 days with RANKL (S.K. Lee, unpublished data).
NFIA is known to repress the differentiation of hematopoietic cells, including
granulocytes and monocytes, and NFIA is a negative regulator of the M-CSF receptor in
osteoclasts (68, 69). Since the M-CSF receptor is a positive regulator of
osteoclastogenesis, the targeting of Nfia by miR-29, like miR-223, could contribute to
differentiation (Figure 3.13A) (53).

70

Figure 3.13. Model of miR-29 regulation of osteoclastogenesis. Schematic
representation of the potential mechanisms regulated by miR-29 in the osteoclast
lineage. A, Cell lineage commitment. B, Cell migration.
In hematopoietic cells, the role of the other two miR-29 targets, CD93 and
GPR85, is less well characterized. However, it is known that CD93 (C1qRp) is a
transmembrane receptor regulating phagocytosis and cell adhesion, and is present on cells
of the myeloid lineage (117). CD93 expression is increased with monocyte differentiation
and macrophage activation (102, 118). Targeting of Cd93 by miR-29 could promote
commitment to osteoclastogenesis, preventing monocytic differentiation. GPR85, also
called SREB2 (superconserved receptor expressed in brain 2) is a G protein-coupled
receptor abundant in neurons, and involved in determining brain size and functionality
(116). In macrophages, GPR85 expression increases upon inflammatory stimulation with
LPS (lipopolysaccharide) (103). Here, we showed that inhibition of miR-29 activity
promotes the commitment of the RAW264.7 cells to the macrophage fate (Figure 3.7). It
is possible that down-regulation of NFIA, CD93, and GPR85 by miR-29 could play a role
in decreasing the potential of the cell to differentiate into the macrophage lineage, thus
promoting osteoclastogenesis (Figure 3.13A).
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Osteoclast migration and fusion require extensive cytoskeletal reorganization, as
does polarization and actin ring formation, initial steps for bone resorption. In this study,
we demonstrated that knock-down of miR-29 family members, through the expression of
an inducible miRNA sponge construct, suppressed the chemotactic migration of
RAW264.7 cells (Figure 3.8). Decreased cell motility in the presence of the miR-29
sponge likely contributed to the observed decrease in osteoclast size. However, not all
functions involved in cytoskeletal remodeling, such as actin ring formation, were affected
by knock-down of miR-29 activity (Figure 3.9B). It is possible that the factors or
pathways specific for regulating actin ring formation may be less affected by miR-29 in
osteoclasts.
Cdc42 was identified as a miR-29 target in humans, and we confirmed miR-29
targeting of the mouse homolog (Figures 3.10 and 3.11) (101). Cdc42 is a small GTPase
that regulates actin remodeling, as well as cell cycle control and survival (119). Although
not required for actin ring formation, Cdc42 regulates the rate of formation, as well as
cell polarization (113). Cdc42 also regulates migration by controlling podosome turnover,
and it is important for the movement of hematopoietic progenitors and macrophages
toward chemotactic signals (120, 121). Although Cdc42 is critical for osteoclast
formation and survival (113), Cdc42 transcript levels in osteoclasts are less than those
found in macrophages or monocytes (122). Further, the levels of Cdc42 mRNA do not
change dramatically during osteoclastic differentiation (123). It is possible that
translational regulation by miR-29 family members could play a role in fine-tuning the
Cdc42 levels during osteoclastogenesis. However, it is also important to consider that
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Cdc42 transcripts are subject to alternative splicing, which can give rise to alternative 3’
UTRs. There is little known about Cdc42 splice variants in cells of the osteoclast lineage.
It is possible that alternative 3’ UTR usage may be one means to vary the ability of
Cdc42 to be targeted by miRNAs.
srGAP2 is one of the novel miR-29 targets identified in this study. srGAP2 is a
Rho-GTPase activating protein that participates in the same signaling pathway as Cdc42
(114). Although srGAP2 function in osteoclasts has not been investigated, it has been
shown to repress cell migration during neuronal development (114, 124) (Figure 3.13,
Table 3.6). Knock-down of miR-29 activity could decrease cell motility, in part, by
causing an increase in srGAP2. Intriguingly, in other cell systems, miR-29 was shown to
target PTEN (tumor-suppressor phosphatase and tensin homolog), a lipid phosphatase
involved in the phosphatidylinositol metabolism. Recent studies identified the
suppression of PTEN as one mechanism by which miR-29 promotes migration in
endothelial cells, breast cancer cells, and hepatocellular carcinoma cells (125). In
RAW264.7 cells, activation of PTEN inhibits RANKL-mediated osteoclastogenesis and
osteopontin-induced migration (126). It is possible that miR-29 knock-down could
increase PTEN levels, and contribute to repressed migration of RAW264.7 cells (Figure
3.13).
It should be noted that our results appear to conflict with a recent report that
lentiviral mediated over-expression of miR-29b in human CD14+ peripheral blood
mononuclear cells reduced osteoclast formation (127). In that paper, Rossi et al. reported
that miR-29b expression decreased during osteoclast formation, and that constitutive
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over-expression of miR-29b decreased the expression of osteoclast marker genes and
impaired collagen degradation. However, the miR-29 over-expression study by Rossi et
al. differs from our work in several key areas. First, Rossi et al. used semi-sorted
circulating human osteoclast precursors from the periphery, whereas we used murine
bone marrow resident osteoclast precursors, which may not circulate. Second, the study
by Rossi et al. did not report on the expression of other miR-29 family members, which
should be present, since miR-29b is transcribed on the same pri-miRNA as miR-29c and
miR-29a. Third, Rossi et al. over-expressed miR-29b. It has been shown that super
physiological expression of a particular miRNA can alter global recruitment of miRNAs
to the RISC (RNA-induced silencing complex), which can confound interpretation of a
resulting cell phenotype (128, 129). Further, knock-down of components important for
miRNA processing, such as DGCR8, Ago2, and Dicer1, inhibits osteoclastogenesis (53).
It is possible that the miR-29b precursor over-expressed by Rossi et al. could compete for
miRNA processing machinery, providing an alternative explanation for the inhibition of
osteoclastogenesis observed by those investigators.
In our study, we observed similar inhibitory effects on osteoclastogenesis when
miR-29a, -29b or -29c were individually targeted by transiently transfected inhibitors
(Table 3.5, Figure 3.3) and when their activity was inhibited by the miR-29 sponge
competitive inhibitor (Figure 3.5C). These data, and the rest of the data herein, strongly
support the conclusion that miR-29 family members promote osteoclastogenesis by
several mechanisms. Whereas some miRNAs may act as “switches” for the commitment
to one cell fate or another, many miRNAs are more subtle regulators of gene expression,
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modulating the amplitude and tempo of a differentiation program (53, 58). miR-29 family
members are likely subtle regulators of multiple osteoclast mRNA targets.
In conclusion, we demonstrated that miR-29 family members sustain migration
and commitment of the precursor to osteoclastogenesis, and we validated 6 novel targets
for this miRNA family. These data contribute to our understanding of the basic
mechanisms regulating osteoclast differentiation, and provide insight into the function of
miR-29 family members in cells of the hematopoietic lineage and in other tissue types.
Dysregulation of miR-29 family members is implicated in the pathology of multiple
malignancies, and in conditions such as diabetes and fibrosis, and aging (130). Additional
studies, in vivo, will better define the role of miR-29 in osteoclastogenesis. It is possible
that increased miR-29 levels could contribute to increased osteoclast formation with
aging (131).
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CHAPTER 4:

Pathway analysis of microRNA expression profile during murine
osteoclastogenesis

CHAPTER ABSTRACT
Osteoclasts are multinucleated cells specialized in degrading the mineralized bone
matrix. Osteoclast differentiation and function are tightly regulated, to prevent excessive
or insufficient bone resorption. Several control mechanisms participate in modulating
osteoclastogenesis, and an increasing number of reports describe the role of microRNAs
(miRNAs) in this process. Disrupting the expression of specific miRNAs can result in
alterations of osteoclast formation and bone homeostasis. We and others have previously
characterized 9 miRNAs whose levels change during osteoclast differentiation, and
identified some of the target genes that mediate their function. However, little is known
about changes in the miRNA expression profile during osteoclastogenesis. In this study,
we isolated a murine primary bone marrow population enriched for osteoclast precursors,
and used the Agilent microarray platform to analyze the expression of mature miRNAs
after 1, 3, and 5 days of RANKL-driven differentiation. 93 miRNAs showed greater than
2 fold-change during these early, middle, and late stages of osteoclastogenesis. Further,
we compared the miRNA expression profile in cultures differentiated for 3 days with M-
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CSF and RANKL and undifferentiated cells cultured with M-CSF alone. 17 miRNAs
showed more than 2 fold-change with RANKL treatment. Many of the miRNAs
differentially regulated in the array were detected for the first time in osteoclasts, and we
validated the expression of selected miRNAs by quantitative RT-PCR. We identified
clusters of differentially expressed miRNAs during the course of osteoclastogenesis, and
performed computational analyses to predict functional pathways that may be regulated
by these miRNAs. Several miRNAs were predicted to regulate genes involved in
cytoskeletal remodeling, a crucial mechanism for the migration of osteoclast precursors,
their maturation, and bone resorbing activity. Our results suggest that clusters of miRNAs
differentially expressed during the course of osteoclastogenesis converge on the
regulation of several key functional pathways. Overall, this study identified miRNAs
expressed during early, middle, and late osteoclastogenesis contributing to our
understanding the molecular mechanisms regulating this complex differentiation process.

INTRODUCTION

The maintenance of bone homeostasis requires a tight control of the number and
activity of osteoblasts, the bone-forming cells, and osteoclasts, the only cells able to
resorb mineralized bone matrix. Osteoclast differentiation is an intricate process,
regulated at multiple levels by transcription factors and post-translational modifications.
In this process, myeloid progenitor cells differentiate into monocytes, commit to the
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osteoclast lineage, migrate, and then fuse into multinucleated polykaryons, at the expense
of the alternative macrophage fate. Several cytokines, including macrophage-colony
stimulating factor (M-CSF, CSF1) and receptor activator of nuclear factor kappa-B ligand
(RANKL), are responsible for driving osteoclastogenesis from multipotential
hematopoietic progenitors. Several intracellular signaling pathways promote commitment
to the osteoclast lineage, and converge on the activation of NFATc1, the master
transcriptional regulator of osteoclastogenesis. NFATc1, in combination with other
transcription factors, including PU.1, MITF, NFκB, and c-Fos, coordinates the expression
of genes necessary for bone resorption, such as Cathepsin K, Tartrate-resistant acid
phosphatase (Acp5, Trap), and Calcitonin receptor (2, 12, 83).
More recently, a growing number of reports have demonstrated the important role
of microRNAs (miRNAs) in osteoclast biology. miRNAs are short sequences of singlestranded, non-coding RNA that act, for the most part, as post-transcriptional regulators of
gene expression. This is achieved primarily by binding target mRNAs at sites frequently
located in the 3’ untranslated region (UTR). However, miRNA binding sequences have
been identified also in the coding region and in the 5’ UTR (84, 132). miRNA activity
requires its incorporation in a RNA-induced silencing complex (RISC). Target
recognition by the miRNA relies mainly on near-perfect base pair complementarity of the
mRNA with the miRNA “seed region”, a 6-8 nucleotide-long sequence in the 5’ end of
the miRNA. Upon target binding, repression of gene expression is accomplished by
suppressing translation, and/or decreasing the stability of the mRNA.
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The critical role of the miRNA processing pathway in the osteoclast lineage was
described. In vitro, silencing of DiGeorge syndrome critical region 8 gene (DGCR8),
Argonaute2 (Ago2), and Dicer1, key miRNA processing factors, decreased
osteoclastogenesis and bone resorption (53). In vivo, deletion of Dicer in the myeloid
lineage, using a CD11b promoter driven-Cre recombinase, and in mature osteoclasts,
using a Cathepsin K promoter driven-Cre, led to the development of mild osteopetrosis,
due to impaired osteoclast differentiation and activity (53, 54). These studies highlight
the overall importance of miRNAs in regulating osteoclast biology, and allude to their
potential as therapeutic targets for pathologies caused by excessive or insufficient
osteoclast activity. However, little is known about the function of individual miRNAs in
osteoclastogenesis.
At the time of this writing, 9 miRNAs and only a few target genes have been
analyzed in the osteoclast lineage (53, 55-58, 61-63, 65). Hundreds of miRNAs have
been identified, and each miRNA can potentially regulate hundreds of mRNAs. Further,
limited information is available about the miRNA expression profile during
osteoclastogenesis, and how it changes during the course of differentiation.
In the present study, we profiled miRNA expression during the early, middle, and
late stages of osteoclastogenesis, in a population of primary murine bone marrow cells
enriched for osteoclast progenitors. We also analyzed changes in miRNA expression in
osteoclast precursors differentiated for 3 days with M-CSF and RANKL, when compared
with undifferentiated cultures. Clusters of differentially expressed miRNAs were
identified, and computational target prediction tools suggest that a set of miRNAs
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expressed in the osteoclast lineage likely regulate pathways critical for cell motility, cellmatrix interactions, axon guidance, and regulation of the actin cytoskeleton.

MATERIALS AND METHODS

Cell Culture.
Primary osteoclast precursor cultures were established using bone marrow from 68 week old C57BL/6 male mice, which had been enriched for osteoclast precursors by
depletion of B220/CD45R-positive and CD3-positive cells (B and T lymphocytes,
respectively). Briefly, bone marrow was isolated from femurs, tibias, and humeri, and
depleted of erythrocytes by treatment with ammonium-chloride-potassium (ACK) buffer
(Gibco Life Technologies, Grand Island, NY) (94). Cells were incubated with
Phycoerythrin (PE)-conjugated primary antibodies for CD45R and CD3 (eBioscience,
San Diego, CA), and with magnetically labeled anti-PE microbeads (MiltenyiBiotec,
Auburn, CA). Magnetic-Activated Cell Sorting (MACS®) Column Technology
(MiltenyiBiotec, Auburn, CA) was used to capture CD45R and CD3 positive cells in the
column, and the flow-through contained a population of cells enriched for monocytic and
non-lymphoid lineage cells. Flow cytometric analysis was performed to analyze the
presence of CD45R and CD3 positive cells. Standard staining procedures were used to
label the cells for flow cytometry. Non viable cells were identified by their ability to
incorporate propidium iodide (PI). Flow cytometry was performed using a BD-FACS
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Aria (BD Biosciences, San Jose, CA, USA), and data were analyzed using FlowJo
software from Tree Star Inc (Ashland, OR, USA). Cells were cultured in α-MEM (Gibco
Life Technologies, Grand Island, NY) supplemented with 10% FBS (Fetal Bovine
Serum, Atlas Biologicals, Fort Collins, CO). Bone marrow-derived osteoclast precursor
cells were cultured in the presence of 30 ng/ml recombinant Macrophage ColonyStimulating Factor (M-CSF) and 30 ng/ml murine recombinant RANKL (eBioscience,
San Diego, CA) for up to 5 days. Bone marrow precursors were also cultured in the
presence of 30 ng/ml M-CSF alone for 3 days.

In Vitro Osteoclast Formation Assay.
Cells were fixed in 2.5% glutaraldehyde in PBS, and TRAP activity was detected
according to the manufacturer’s instructions using the Acid Phosphatase Leukocyte
(TRAP) kit (Sigma-Aldrich). Osteoclast cultures were imaged using light microscopy.

miRNA Microarray.
Primary osteoclast precursors were plated at 53,000 cells/cm2. Total RNA was
isolated from differentiating cultures using the miRNeasy Mini kit (Qiagen, Valencia,
CA). On-column DNase treatment was performed to reduce contamination with genomic
DNA, and an additional treatment with RQ1 DNase (Promega, Madison, WI) was
performed prior to gene expression analysis. RNA concentration and purity were assessed
by spectrophotometric analysis. The quality of small RNAs in each sample was
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determined using the 2100 Bioanalyzer assay (Agilent Technologies, Santa Clara, CA).
200 ng of total RNA were labeled using miRNA Microarray System with miRNA
Complete Labeling and Hyb Kit (Agilent Technologies). According to the manufacturer’s
instructions, the samples were hybridized for 20 hours onto a mouse miRNA Microarray,
Release 15.0, 8x15K (based on Sanger miRBase release 15.0), containing 627 mouse
mature miRNA probes (Agilent Technologies). Hybridized and washed array slides were
scanned at 5 µm resolution using an Agilent SureScan Microarray Scanner (Agilent
Technologies). Image processing was completed using Feature Extraction Software
(Agilent Technologies). We acknowledge Dr. David Willmot for technical assistance
with the microarray analysis.

Microarray Data Analysis.
Microarray data were normalized and analyzed using the GeneSpring GX
software (Technology 29152_v.17_0, Agilent Technologies). 4 biological replicates were
used for each sample set. miRNAs detected in at least one sample were subjected to
quantile normalization to allow comparison between the microarray chips, and relative
expression is presented as log(base 2). One-way Analysis of Variance (ANOVA) was
performed on miRNAs expressed during the time course of osteoclast differentiation
analyzed (days 1, 3, and 5). Student’t t test was performed on miRNAs expressed in
undifferentiated (cultured in the presence of M-CSF alone) and differentiated (cultured in
the presence of M-CSF and RANKL). For both data sets, miRNAs showing >2 or <-2
fold-change, with p<0.01, were considered statistically significant. A hierarchical
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clustering analysis was used to organize the genes based on similarities in their
expression profiles. A list of putative miRNA targets was identified using the prediction
algorithm DNA Intelligent Analysis (DIANA) DIANA-microT-CDS (v5.0). The
predicted miRNA targets were annotated into functional pathways using DIANAmiRPath

(v2.0)

(http://diana.imis.athena-

innovation.gr/DianaTools/index.php?r=site/index). The complete data set has been
submitted to NCBI-GEO (National Center for Biotechnology Information – Gene
Expression Omnibus), and is available at the accession number GSE53017.

Quantitative Real time PCR.
miRNA expression levels were analyzed using the TaqMan MicroRNA Assay
(Life Technologies, Grand Island, NY). According to the manufacturer’s instructions,
22.5 ng of RNA were reverse transcribed with specific primers to generate cDNA. The
expression of miR-365, miR-99b, and miR-451 was detected by qPCR in a MiQ qPCR
cycler (Bio-Rad) and normalized to U6 small nuclear RNA (RNUB6) levels, using the
absolute quantification method. Data are presented as mean ± SEM. Data were analyzed
by one-way ANOVA with Bonferroni post-hoc test as appropriate (KaleidaGraph,
Synergy Software, Reading, PA).
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RESULTS AND DISCUSSION

Differential miRNA expression during in vitro osteoclastogenesis.
Mouse bone marrow is a widely used source of primary osteoclast progenitors
for in vitro analyses. However, bone marrow represents a highly heterogeneous
population, containing not only monocytes, but also megakaryocyte precursors,
terminally differentiated macrophages and neutrophils, and, in higher percentage,
lymphocytes. Our unpublished results indicate that 25-30% of total bone marrow is
B220+ and 5-7% is CD3+ after erythrocyte depletion (Dr. S.K. Lee, personal
communication, unpublished data). In addition, the majority of the efficient osteoclast
precursors is contained within the B220-/CD3-/CD11b-/lo population in the bone marrow
(43, 133). Therefore, we sought to decrease the heterogeneity of this precursor
population, prior to the initiation of osteoclastogenesis, by depleting the lymphocytic
cells. Mouse bone marrow cells were subjected to MACS sorting using CD45R and CD3
antibodies. Flow cytometric analysis confirmed that this procedure depleted 93-95% of T
and B cells, thereby decreasing the heterogeneity of the marrow cells that were
subsequently plated for experiments (Figure 4.1A). We cultured mouse bone marrowderived osteoclast precursors in the presence of M-CSF and RANKL for up to 5 days. At
days 1, 3, and 5 of culture, osteoclast formation was monitored by TRAP staining, and
total RNA was harvested (Figure 4.1B). Under these conditions, osteoclast number
increased progressively, and mRNA levels for the osteoclast markers TRAP and
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Cathepsin K were increased from day 1 to day 3, and maintained at day 5, as we
previously reported (62) (Figure 3.2E,F).

Figure 4.1. MACS sorting depleted lymphocytes from bone marrow-derived
osteoclast cultures. (A) Bone marrow cells were depleted of CD45R+ and CD3+ cells by
MACS sorting, using CD45R and CD3 antibodies. The negative population, constituted
by non-lymphoid cells and enriched for monocytes, was collected and analyzed by flow
cytometry. The gated population identifies the CD45R/CD3+ cells (purple) (n=3). (B)
The enriched population of bone marrow-derived osteoclast precursors was
differentiated in the presence of 30 ng/ml, each, M-CSF and RANKL for up to 5 days.
Representative images of TRAP stained cultures after 1, 3, and 5 days of differentiation
were captured using 10X magnification. Scale bar, 100 µm (n=3).
The Agilent mouse miRNA microarray that we used contained 627 probes for
mature miRNAs. In our sample set, 258 miRNAs were significantly detected at least at
one time point. 142 of these miRNAs were significantly changed during the time course
investigated, and several were identified for the first time in the osteoclast lineage.
Among the significantly changed miRNAs, 93 miRNAs showed > ± 2 fold-change. 49
miRNAs were up-regulated over time, whereas 44 were down-regulated (Figure 4.2).
In regards to miRNA expression after 3 days in culture, 43 miRNAs were
significantly changed with M-CSF and RANKL treatment in comparison with M-CSF
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Figure 4.2. miRNA expression profiles during osteoclastogenesis. (A) Heat map of
the 93 miRNAs showing > ± 2 fold-change over 5 days of osteoclast differentiation.
Fold-change was calculated between day 1 and day 3, day 1 and day 5, and day 3 and
day 5. Hierarchical cluster analysis on gene expression divided the miRNAs in 7 groups.
Blue represents low expression, red high expression, and yellow intermediate
expression. (B) Schematic overview of the microarray results.
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treatment alone, and 17 miRNAs showed > ± 2 fold-change. 9 miRNAs were upregulated in the presence of RANKL, whereas 8 were decreased (Figure 4.3).

Verification of the microarray results.
To verify the results of the microarray experiment, we used quantitative RT-PCR
(qRT-PCR) to confirm changes in the levels of 3 miRNAs, the expression of which had
not been previously reported in the osteoclast lineage: miR-365, miR-99b, and miR-451
(Figure 4.4, Table 4.1). We observed that miR-365-3p and miR-99b-5p were 2 miRNAs
strongly up-regulated in day 5 cultures (Figures 4.8A, 4.9A). qRT-PCR confirmed that
their levels increased 12 fold in the differentiating cultures (Figure 4.4A). Further, the
expression of miR-365 and miR-99b was significantly induced by 3 days of M-CSF and
RANKL treatment, when compared with cells cultured in the presence of M-CSF alone
(Figure 4.4C,D). This suggests that the up-regulation of miR-365 and miR-99b levels
during the course of osteoclastogenesis is likely associated with the progression of the
differentiation program, rather than time in culture.
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The function of miR-365 in
osteoclastogenesis

or

in

hematopoietic cells has not been
investigated. However, we found
this miRNA was of interest because,
although

mature

miR-365

is

transcribed from two independent
genetic loci (on mouse chromosomes
11 and 16), the expression of miR365 from the chromosome 16 locus
is activated by Sp1 and NFκB, two
transcription factors that promote
osteoclastogenesis (29, 134). miR99b was of interest because it is upregulated in dendritic cells and
monocytes

during

inflammation

(135, 136). Further, TNFα (tumor
necrosis factor α) signaling is a key
pathway

in

promoting

osteoclastogenesis, and Tnfα, Tnfrsf4
(Tumor Necrosis Factor Receptor
Superfamily, Member 4), and Traf2

Figure 4.3. miRNA expression profile after 3
days of culture with M-CSF and RANKL. Heat
map of the 17 miRNAs showing > ± 2 foldchange in the presence or absence of RANKL.
Hierarchical cluster analysis grouped the
miRNAs based on their expression levels. Blue
represents low expression, red high expression,
and yellow intermediate expression.
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Figure 4.4. Validation of miRNA microarray results. (A,B) The expression of
selected miRNAs that changed > ± 2 folds during the course of osteoclastogenesis was
analyzed by qPCR. (A) miR-365 and miR-99b expression; (B) miR-451 expression. (CE) Selected miRNAs that showed greater than ± 2 fold-change in cells treated with MCSF and RANKL (M+R) versus cells treated with M-CSF (M) alone for 3 days were
quantified. (C) miR-365 expression; (D) miR-99b; (E) miR-34b. Gene expression was
normalized to U6. n=4; * significantly different from day 1 (p<0.01).
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(TNF receptor-associated factor 2), were recently identified as miR-99b targets in other
cell types (136-139). Interestingly, miR-99b is transcribed in an evolutionary conserved
cluster that includes let-7e and miR-125a, all of which were significantly up-regulated
during osteoclastogenesis, as assessed by our microarray (Figure 4.7A) (140).
In contrast, miR-451 expression was dramatically decreased over 5 days of
osteoclast differentiation (Figure 4.4B). Several reports have revealed that miR-451
expression is required for erythroid differentiation and homeostasis (141, 142).
Therefore, it is possible that the high levels of miR-451 detected at day 1 are due to the
presence of erythrocyte precursors in the cultures, which will not survive the
differentiation with M-CSF and RANKL. Indeed, we could not detect expression of miR451 by qRT-PCR in the bipotential mouse monocytic cell line RAW264.7 (data not
shown).
In regard to miRNAs significantly changed at day 3 of differentiation with MCSF and RANKL, in comparison with undifferentiated cultures, we confirmed that miR34b-5p is significantly increased in the presence of RANKL (Figure 4.3, Figure 4.4E).
miR-34b belongs to the miR-34 family of miRNAs, which were previously identified as
principal players in the p53-mediated regulation of apoptosis (143). The role of miR-34b
in the osteoclast lineage is unknown. However, the function of miR-34b in the regulation
of hematopoiesis has been investigated. The genomic region encoding for the miR-34b
gene is frequently deleted in chronic lymphocytic leukemia, and miR-34b targets the antiapoptotic gene Tcl-1 (T-cell leukemia/lymphoma 1) (144). In addition, miR-34b inhibits
the expression of CREB (cAMP response element-binding protein), a key transcriptional
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Table 4.1. Changes in miRNA profile during the progression of murine
osteoclastogenesis, confirmed by other microarray studies. Published studies in
RAW264.7 cell line and mouse bone marrow macrophages (BMMs) confirm the
expression pattern for 17 of the 97 miRNAs regulated during the course of
osteoclastogenesis (61, 67).
miRNA

Expression during
osteoclastogenesis

Experimental system

References

let-7a-5p

↑

BMMs, RAW264.7

(61, 67)

let-7e-5p

↑

BMMs, RAW264.7

(61, 67)

let-7f-5p

↑

BMMs, RAW264.7

(61, 67)

miR-100-5p

↑

RAW264.7

(67)

miR-125a-5p

↑

RAW264.7

(67)

miR-125b-5p

↑

RAW264.7

(67)

miR-146a-5p

↑

RAW264.7

(67)

miR-146b-5p

↓

RAW264.7

(67)

miR-185-5p

↑

RAW264.7

(67)

miR-29b-3p

↑

RAW264.7, bone marrow-derived
osteoclast precursors

(62, 67)

miR-338-3p

↓

RAW264.7

(67)

miR-365-3p

↑

RAW264.7

(67)

miR-378-3p

↑

RAW264.7

(67)

miR-674-3p

↑

RAW264.7

(67)

miR-689

↓

RAW264.7

(67)

miR-98-5p

↑

BMMs, RAW264.7

(61, 67)

miR-99a-5p

↑

RAW264.7

(67)
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regulator of hematopoiesis (145). These observations indicate that proper expression of
miR-34b is necessary for the progression of hematopoietic differentiation. Therefore,
changes in the expression of miR-34b may be involved in the control of
osteoclastogenesis.
We compared our microarray results with other published murine miRNA profile
analyses in osteoclastic cultures. The expression pattern that we observed for 17 of the
significantly regulated miRNAs was similar to what observed in a 24 or 82 hour
RANKL-driven RAW264.7 cell differentiation, and in a 24-hour RANKL-treatment of
bone marrow macrophages (Table 4.1) (61, 67). However, a few discrepancies were
noted in miRNA expression trends between our microarray data and those published by
other investigators. These are likely attributable to differences in the experimental
designs, most notably differences in the percentage of osteoclast precursor cells used and
the time in culture. Our study is unique in that we analyzed an enriched population of
primary osteoclast precursors from the bone marrow, and evaluated miRNA expression
during early, middle, and late phases of differentiation.

Target prediction and correlated pathways for miRNA expression clusters.
The 93 miRNAs that showed greater than ± 2 fold-change with osteoclast
differentiation were analyzed by hierarchical clustering. Based on their level of
expression and change during differentiation, the miRNAs were divided into 7 clusters
(Table 4.2, Figures 4.5-4.11, Figure 4.2). In an attempt to understand how these changes
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in miRNA expression might
influence

osteoclastogenesis,

we performed a computational
target

prediction

analysis.

Potential target RNAs for upor down-regulated miRNAs
from

each

cluster

were

identified using the prediction
algorithm

DIANA-microT-

CDS (v5.0). This algorithm

Table 4.2. miRNA clusters. Hierarchical clustering of
the miRNAs significantly changed during osteoclast
differentiation generated 7 subgroups.
Cluster number

Name/Description

1

Highly expressed

2

Modestly expressed down-regulated

3

Modestly expressed up-regulated

4

Well expressed up-regulated

5

Well expressed down-regulated

6

Most down-regulated over time

7

Most up-regulated over time

recognizes potential miRNA
binding sites located in the coding sequence and in the 3’ UTR of an mRNA, based on
complementary pairing with nucleotides in position 1-9 at the 5’ end of the miRNA (i.e.
the seed binding region). Additional features taken into consideration include
conservation of the sequence element across species and accessibility of the target site
(146, 147). The potential miRNA targets for each miRNA cluster were then subjected to
KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway analysis, using the
DIANA-miRPath (v2.0) software. This algorithm calculates the significance for all the
miRNA-mRNA pairs in a pathway, and then combines them into a merged P-value for
each pathway (148). The results are reported as heat maps, and the pathways are clustered
based on significance levels. The more intense red color indicates higher probability that
a specific pathway is significantly enriched with target genes for a certain miRNA.
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Figure 4.5. Cluster 1, highly expressed miRNAs during osteoclastogenesis. (A)
miRNA heat map. The dendrogram shows the similarities between the expression
profiles of the significantly changed miRNAs. Down-regulated miRNAs are indicated
by the “*” symbol. Blue represents low expression, red high expression, and yellow
intermediate expression. (B) Up-regulated miRNAs and predicted pathways heat map.
Red color indicates lower p values (more significant), and higher interaction of each
miRNA with a specific molecular pathway. (C) Down-regulated miRNAs and predicted
pathway heat map. Significant miRNA-pathway interaction p<0.001.
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Cluster 1 is composed of highly expressed miRNAs, and contains miRNAs that
are both up- and down- regulated during osteoclastogenesis. Therefore, separate pathway
analysis was performed for the up- and down- regulated miRNAs. Among the highly
expressed and up-regulated miRNAs is miR-29b, a member of the miR-29 family (Figure
4.5A). We and others previously showed that the expression of all miR-29 family
members increases during osteoclastogenesis (62, 67) (Figure 3.2A). In addition, we
demonstrated that miR-29 promotes osteoclast commitment and migration, and is critical
for osteoclast formation. We validated several novel miR-29 targets in the osteoclast
lineage, including calcitonin receptor. Further, miR-29 targets genes important for the
macrophage lineage, Nfia (Nuclear factor 1/A), Cd93, and Gpr85 (G protein coupled
receptor 85); and genes modulating cell migration, including Cdc42 (Cell division control
protein 42) and Srgap2 (SLIT-ROBO Rho GTPase activating protein 2) (62). With regard
to miR-29b, the pathway analysis suggests that functions such as cell-matrix interactions,
focal adhesion, and PI3K/Akt, to be most significantly associated with miR-29 (Figure
4.5B). Several predicted miR-29 targets within these pathways have been experimentally
confirmed. These include mRNAs for a large number of extracellular matrix proteins
(collagens, laminins), the tumor suppressor Pten, Igf1 (insulin growth factor 1), and Mcl1
(myeloid cell leukemia 1) (149-152). Overall, these observations suggest that the
pathway prediction analysis for the individual miRNAs is, at least in part, validated by
experimental data.
The validity of this pathway clustering approach is further supported by analysis
of the miRNA family formed of miR-99a, miR-99b, and miR-100. Each these miRNAs is
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Figure 4.6. Cluster 2,
modestly expressed
miRNAs downregulated during
osteoclastogenesis.
(A) miRNA heat map.
Blue represents low
expression, red high
expression, and yellow
intermediate expression.
(B) Predicted pathways
heat map. Red color
indicates
lower
p
values.

up-regulated during the course of osteoclastogenesis, although with different amplitude.
miR-99a-5p belongs to expression cluster 4, miR-99b-5p to cluster 7, and miR-100-5p to
cluster 3 (Figures 4.7A, 4.8A, and 4.11A). KEGG pathway analysis predicted, with a
high degree of confidence (p<0.001), miR-99b regulation of the mTOR (mammalian
target of rapamycin) pathway, whereas association of miR-99a and miR-100 with the
mTOR pathway was predicted with lower confidence (p<0.005) (Figures 4.7B, 4.8B, and
4.11B). Remarkably, several studies demonstrated the role of the miR-99 family in
repressing mTOR signaling in different cell systems, including wound healing
keratinocytes, as well as prostate, endometrial, and pancreatic cancer cells (153-156). In
our study, numerous clusters of miRNAs, both up- and down-regulated during the course
of osteoclast differentiation, were predicted to target components of the mTOR pathway.
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Cluster 4 appears to be particularly enriched in miRNAs with potential targets in the
mTOR pathway (Figure 4.8B). Clusters of differentially regulated miRNAs are predicted
to target both positive and negative regulators of the mTOR pathway, as represented in
the diagram in Figure 4.12.

Figure 4.7. Cluster 3, modestly expressed miRNAs up-regulated during
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red
color indicates lower p values.
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Figure 4.8. Cluster 4, well expressed miRNAs up-regulated during
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red
color indicated lower p values.
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Figure 4.9. Cluster 5, well expressed miRNAs down-regulated during
osteoclastogenesis. (A) miRNA heat map. Blue represents low expression, red high
expression, and yellow intermediate expression. (B) Predicted pathways heat map. Red
color indicates lower p values.
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Figure 4.10. Cluster 6, miRNAs most down-regulated during osteoclastogenesis.
(A) miRNA heat map. Blue represents low expression, red high expression, and yellow
intermediate expression. (B) Predicted pathways heat map. Red color indicates lower p
values.
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Figure 4.11. Cluster 7, miRNAs most up-regulated during osteoclastogenesis. (A)
miRNA heat map. Blue represents low expression, red high expression, and yellow
intermediate expression. (B) Predicted pathways heat map. Red color indicates lower p
values.
In osteoclasts, mTOR has been implicated in the regulation of apoptosis. Crucial
signaling pathways triggered by M-CSF, RANKL, and TNFα converge on the activation
of S6K (p70 ribosomal protein S6 kinase), a main effector of the mTOR signaling
cascade. By regulating the process of translation, mTOR promotes osteoclast
differentiation, survival, and bone-resorbing activity (157, 158). Although miRNAmediated modulation of mTOR factors has been widely investigated in other biological
systems, this represents a novel area of research in the bone field.
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Figure 4.12. Positive and negative regulators of the KEGG mTOR signaling
pathway are potential targets of up- and/or down-regulated miRNA clusters.
KEGG pathway analysis showed that several miRNAs from clusters 1, 3, and 4
were predicted to target extracellular matrix-receptor interactions, regulators of the actin
cytoskeleton, focal adhesion, and axon guidance (Figures 4.5B,C, 4.7B, 4.8B). As a
representative example, the predicted target genes in the axon guidance pathway are
depicted in Figure 4.13. Pathway prediction analysis indicated that both genes with a
positive and negative role in axon guidance were predicted to be regulated by
differentially expressed miRNAs. This suggests that further analyses are necessary to
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Figure 4.13. Positive and negative regulators of the KEGG axon guidance pathway
are potential targets of up- and/or down-regulated miRNA clusters.
validate the individual miRNA-target interactions and the function of clusters of miRNAs
in regulating this pathway.
Likewise, pathway analysis for miRNAs up- and down-regulated after 3 days of
osteoclastogenic differentiation with M-CSF and RANKL indicated that focal adhesion
and axon guidance were predicted targets for various miRNAs (Figure 4.14). Osteoclasts
do not use focal adhesions to adhere to the bone surface. However, several proteins that
belong to the KEGG functional pathway for focal adhesion participate in the formation of
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Figure 4.14. Pathway prediction analysis for miRNAs differentially expressed
after 3 days of M-CSF and RANKL treatment versus M-CSF alone. (A) Upregulated miRNAs and predicted pathways heat map. (B) Down-regulated miRNAs
and predicted pathways heat map. Red color indicates lower p values.
podosomes and actin rings, which are critical for osteoclast adhesion. These include
integrins and proteins of the Rho GTPase signaling pathway. Similarly, although axon
guidance is usually studied in regard to neuronal development, numerous factors within
this KEGG pathway play an essential role in the osteoclast lineage, such as ephrins,
semaphorins, and Rho GTPases (76, 159, 160). Moreover, many signaling cascades that
regulate focal adhesion and axon guidance, as well as extracellular matrix-receptor
interaction, converge on reorganization of the actin cytoskeleton. This is a key process
that regulates a variety of biological functions, including cell motility, morphology, and
attachment, as well as gene expression, differentiation, and apoptosis. Cytoskeletal
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remodeling and cell migration are fundamental for osteoclast formation and bone
resorption activity, and they are tightly controlled at multiple levels (161). We and others
have previously shown that miRNAs can modulate osteoclast motility and activity (55,
62, 63). However, a complete understanding of the miRNAs involved in fine tuning the
regulation of cytoskeletal reorganization is lacking. Our study contributes to the
identification of miRNAs that may play a role in this function.
We performed pathway analysis on miRNAs down-regulated upon 3 days of
RANKL treatment. This revealed that the KEGG pathway for osteoclast differentiation
was predicted to be regulated by a subset of miRNAs, miR-340-5p, miR-362-3p, miR500-3p, which had previously not been investigated in osteoclasts or in hematopoiesis
(Figure 4.14B). Predicted targets for these miRNAs include proteins involved in signal
transduction for the PI3K/Akt signaling and the MAPK signaling, transcription factors
such as Nfatc1, c-Fos, and Nfκb, and osteoclast markers like calcitonin receptor and
integrin β3. Although, further experimental validation is needed, these data suggest that
this subset of miRNAs may be critical in the regulation of osteoclastogenesis.

CONCLUSIONS

Osteoclastogenesis is an intricate multi-step process, initiating with the
proliferation and commitment of mononucleated precursors, and culminating in the
formation of large bone-resorbing polykaryons. In this study, we identified a profile of
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miRNAs differentially expressed in the various stages of osteoclastogenesis in primary
cultures. Pathway analysis showed that a large number of miRNAs detected in the
microarray were predicted to target genes involved in the interaction between cells and
extracellular matrix, axon guidance, focal adhesion, and remodeling of the actin
cytoskeleton. An increasing number of studies have revealed the relevance of miRNAs in
osteoclast biology, making them appealing targets for the development of therapeutic
strategies for bone disease. However, our knowledge of the function of specific miRNAs
in this lineage is still limited. This study provides important information on miRNAs with
the potential to regulate osteoclast differentiation; such information will contribute to the
development of therapies for skeletal pathologies caused by alterations in bone resorption
activity.
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CHAPTER 5:

SUMMARY, SIGNIFICANCE, AND CONCLUSIONS

Summary

The purpose of the studies described in this dissertation was to improve our
knowledge of the molecular mechanisms by which miRNAs regulate genes important for
osteoclast differentiation and function.
First, we determined that the miR-29 family members, miR-29a, -29b, and -29c,
increase during murine osteoclastogenesis. We also showed that inhibition of miR-29
family members impairs osteoclast formation in vitro. In addition, we developed a stably
transduced RAW264.7 cell line expressing a doxycycline-inducible miR-29 competitive
inhibitor (sponge construct). Using this cell line as a tool, we showed that miR-29 knockdown inhibits commitment and migration of osteoclasts precursors. However, miR-29
knock-down does not affect cell viability, actin ring formation, or apoptosis in mature
osteoclasts. We also identified six novel miR-29 targets, which play a role in mediating
its function in the osteoclast lineage. These include RNAs critical for cytoskeletal
organization, such as Cell Division Control protein 42 (Cdc42) and SLIT-ROBO Rho
GTPase activating protein 2 (Srgap2). Moreover, miR-29 targets RNAs associated with
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the macrophage lineage: G protein-coupled receptor 85 (Gpr85), Nuclear Factor I/A
(Nfia), and Cd93. In addition, Calcitonin receptor (Calcr), which regulates osteoclast
survival and resorption, is a novel miR-29 target. Thus, we identified miR-29 as a
positive regulator of osteoclast formation, which inhibits RNAs important for
cytoskeletal organization, commitment, and osteoclast function (Chapter 3) (62).
Second, we isolated a murine primary bone marrow population enriched for
osteoclast precursors, and analyzed the expression of mature miRNAs during the early,
middle, and late stages of osteoclastogenesis. Further, we compared the miRNA
expression profile in day 3 undifferentiated and differentiated cultures of osteoclast
precursors. We identified clusters of differentially expressed miRNAs during the course
of osteoclastogenesis, and performed computational analyses to predict functional
pathways that may be regulated by these miRNAs. Several miRNAs were predicted to
regulate genes involved in cytoskeletal remodeling, a crucial process for the migration of
osteoclast precursors, their maturation, and bone resorbing activity. Therefore, miRNA
profiling of differentiating osteoclast precursors highlighted novel miRNAs that may
regulate osteoclast differentiation and function (Chapter 4).
The main challenge in understanding the functional significance of alterations in
the miRNA expression profile is the identification of target mRNAs. A single miRNA
can regulate the expression of several hundred genes, and validation of true miRNAmRNA target interactions requires experimental approaches similar to the ones used in
Chapter 3. To determine potential miRNA-mRNA interactions for analysis,
computational target prediction is usually the first step, since it helps develop the
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hypotheses. This approach is biased by the design of the algorithm used, and frequently
by the investigator’s interest in specific genes or biological mechanisms. Alternatively,
pull-down assays for the proteins involved in miRNA biogenesis, such as Argonaute2,
can be used to identify physical interactions between miRNAs and mRNA sequences
(162). Both of these methods present advantages and limitations.
For example, computational analysis evaluates hundreds of genes at the same
time; although the results of such analyses include a large number of false positive and
false negative interactions. Thus, it is necessary to directly validate the predicted miRNAmRNA interactions (162, 163). Pull-down assays, on the other hand, can lead to the
identification of direct miRNA binding sequences in target mRNAs in the cell. However,
this type of analysis is technically challenging, demands a high level of expertise, and
additional tests are required to confirm that the identified miRNA-mRNA interactions
actually regulate the protein product (163).
A more comprehensive approach would combine proteomic analyses with
computational target prediction and miRNA expression data, generated by microarray or
deep-sequencing. This approach could reveal an inverse relationship between the
expression of a certain miRNA and potential mRNA and protein targets in the data set.
For example, a recent study by Ou et al. integrated miRNA deep-sequencing results on
PBMCs from osteopetrotic patients with quantitative proteomics and bioinformatics for
target prediction. Here, a reciprocally expressed miRNA-target pair was identified. miR320a was decreased in osteopetrosis, whereas the Ras-like GTPase ARF1 (ADP
ribosylation factor 1) was up-regulated. Arf1 was identified as a novel miR-320a target,
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and it belongs to a family of GTPases important in the regulation of osteoclast
polarization and formation of the sealing zone (64, 164). Such studies in osteoclasts could
help identify new miRNAs and target genes important in the development of pathological
conditions, and potential candidates for therapy.

Significance

We and others demonstrated that miRNAs are essential regulators of cell
differentiation and activity. In addition, alterations in miRNA expression are often
detected in pathological conditions, including degenerative diseases, cancer, and autoimmune conditions (8). Due to their ability to regulate cell physiology and their
documented dysregulation in disease, miRNAs appear as attractive candidates for the
development of diagnostic and prognostic tools, as well as for the development of
miRNA-based therapeutics. With regard to miRNA-based therapeutics, the potentially
pathological effect of a miRNA over-expressed during disease could be blocked by
specific inhibitors, whereas the levels of a miRNA down-regulated during pathogenesis
could be restored using mimics. In this way, it may be possible to modify the miRNA
levels and, as a consequence, change the phenotype of a particular cell or tissue.
We showed that the miR-29 family of miRNAs promotes osteoclast
differentiation (62). Therefore, understanding the mechanisms by which miR-29 exerts its
positive effect on osteoclastogenesis may aid in the design of therapeutic strategies for
bone diseases associated with alterations of the osteoclast compartment.
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miRNA-based therapeutics in clinical trials.
At the time of this writing, two miRNA-based therapeutics have been used in
clinical trials. Miravirsen, a locked nucleic acid (LNA) inhibitor oligonucleotide for miR122, is the most clinically advanced miRNA-based drug. Currently in clinical phase 2a
trial, Miravirsen is designed to repress miR-122, which is highly expressed in the liver.
Here, miR-122 targets the hepatitis C virus (HCV) in infected patients and protects it
from degradation. By sequestering miR-122, Miravirsen blocks HCV replication, and
repress the viral infection (Santaris Pharma A/S) (165).
Recently, the first miRNA mimic entered clinical phase 1 trial. MRX34 is a
double-stranded RNA mimicking the sequence of miR-34. miR-34 is down-regulated in a
variety of tumors, and more than 20 oncogenes were identified as direct targets. MRX34
is delivered using an amphoteric liposomal carrier formulation, which is positively
charged in an acidic environment. Since tumors often have low pH, this design facilitates
MRX34 uptake in cancer cells, but not in normal cells (miRNA Therapeutics, Inc.) (166).
The development of therapeutics based on miRNAs faces many challenges. In
pre-clinical studies, most approaches have used oligonucleotides designed to inhibit a
specific miRNA or to mimic its sequence. For safety reasons, this strategy is usually
preferred to the use of viral expression constructs. However, chemical stabilization of the
oligonucleotide RNA molecules is necessary to avoid their degradation and decrease
immunogenicity (167). Another difficulty centers on the delivery of the miRNA
therapeutic.
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Delivery of miRNA-based therapeutics.
The most recent delivery methods for nucleic acid-based drugs, investigated
primarily for small interference RNAs (siRNAs), consist of the conjugation of the RNA
molecules with cationic lipids or natural and synthetic polymers, to form nanoparticles.
Lipids and polymers may be used both as delivery carriers and as modification agents.
Common polymers used include polyethylenimine (PEI), composed of repeated amine
groups, poly(lactide-co-glycolide) (PLGA), chitosan, atelocollagen, and protamine.
Alternatively, the RNA sequences can be fused to proteins or aptamers, which are
structured nucleic acid or peptide molecules, which can be recognized by specific surface
receptors. These delivery methods have been explored in several cell types, including
hepatocytes, breast cancer cells, T lymphocytes, and osteoblasts (167).
In selecting an appropriate delivery system, it is important to choose an approach
that is efficient, but that also allows the targeting of the nucleic acid to the tissue of
interest. Localized delivery and release of the miRNA mimics or inhibitors is necessary
to reduce systemic side effects. For the same reason, in the perspective of using miRNAs
for the development of therapeutics, the identification of miRNA target genes is critical.
Although the function of a specific miRNA is known in a particular cell type or tissue,
unpredictable effects could occur due to the regulation of unknown targets.
In the skeleton, cell-specific delivery is especially difficult because of the
complexity of the microenvironment. Recently, RNA-based molecules have been used to
improve bone formation in an animal model. siRNA for pleckstrin homology domaincontaining family O member 1 (Plekho1) was selectively delivered to osteoblasts, but not
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to osteoclasts, using cationic liposomes conjugated with six repetitive sequences of
aspartate, serine, serine, (Asp,Ser,Ser)6 (168). This oligopeptide was shown to
preferentially bind lowly crystallized hydroxyapatite and amorphous calcium
phosphonate, which are characteristics of bone-forming surfaces (169). In contrast, a
sequence of eight repeats of aspartate (Asp8) has strong affinity for highly crystallized
hydroxyapatite, such as that found on osteoclast-rich bone-resorbing surfaces (170).
These differences allow the specific targeting of surfaces covered mainly by osteoblasts
or osteoclasts.
In another study, siRNA against RANK was delivered to osteoclast precursors
and mature osteoclasts in vivo, using PLGA microparticles and calcium-based injectable
cement. Here, the siRNA retained its biological activity, and repressed the expression of
RANK (171). In vitro, siRNA for RANK was shown to inhibit osteoclast formation and
bone resorption activity (172). However, the efficacy of these molecules on osteoclast
differentiation and function has not been tested in an in vivo model.
Targeting common precursors, rather than differentiated osteoclasts, could
represent another strategy for affecting osteoclast number. A few studies have selectively
delivered siRNA molecules to leukocytes, taking advantage of antibodies directed against
cell-surface antigens, such as integrin lymphocyte function-associated antigen-1 (LFA-1),
fused to protamine molecules (173). In another report, Peer and colleagues delivered
siRNA by means of liposomes covalently bound to anti-β7 integrin antibodies (174).
Although these and other strategies can be used to deliver RNA-based drugs to
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hematopoietic cells, selective targeting of cells of the monocytic lineage has not been
reported.
We showed a positive role for miR-29 in the osteoclast lineage, and demonstrated
that its knock-down strongly affects osteoclast differentiation in vitro. Our data suggest
that miR-29 could be targeted in the development of therapies for pathological conditions
characterized by extensive, aberrant bone resorption. Systemic bone loss can be caused
by excessive osteoclast number or activity, as in the case of post-menopausal
osteoporosis. In contrast, localized bone loss can occur in rheumatoid arthritis and
periodontal disease, and cause joint damage and tooth loss. miRNA-based therapies
appear especially appealing for structures like the articular joints or the mandible, since
the delivery of the miRNA mimics or inhibitors could be confined to these localized
areas.
However, our laboratory and others previously demonstrated that miR-29 also
mediates the differentiation of osteoblasts. Therefore, in the use of miR-29 inhibitors to
repress osteoclastogenesis, it would be particularly important to deliver the RNA
molecules only to the bone resorbing cells. Potentially, the delivery of a miR-29 inhibitor
to the bone remodeling units would result in reduced bone turnover, leading to increased
bone fragility.
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Conclusions

The studies presented in this dissertation are unique in that we described the
molecular mechanisms by which a family of miRNAs, miR-29a, -29b, and -29c, supports
osteoclastogenesis, and we identified six novel target genes that may mediate this
function. This work not only expands our knowledge of the role of miRNAs in the
osteoclast lineage, but it also helps us better understand the basic molecular workings
regulating cell differentiation, which could be applicable in other cell types.
In addition, we profiled miRNA expression in a primary bone marrow population
enriched for osteoclast precursors, and characterized how this profile changes during the
early, middle, and late phases of osteoclastogenesis. We showed that clusters of
differentially expressed miRNAs could potentially regulate numerous genes involved in
actin reorganization and cell motility. Thus, we highlighted novel miRNAs that may play
a critical role in osteoclasts.
Maintaining the delicate balance between bone formation and resorption is critical
for bone health. In pathological conditions this becomes unbalanced, and the
development of therapeutic strategies able to restore this homeostasis relies on a thorough
understanding of the molecular mechanisms of osteoblast and osteoclast differentiation.
Our research contributes to this goal by providing new data on the function of miRNAs in
the osteoclast lineage.
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